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ABSTRACT 
 
 The purpose of this study was to determine the effects of following either the 
Curves® Fitness and Weight Management Plan or the Weight Watchers® Momentum™ 
Plan on body composition and markers of health and fitness in previously sedentary 
obese women.  Fifty-one women (age 35±8 yrs; height 163±7 cm; weight 90±1 kg; BMI 
34±5 kg/m2; 47±7% body fat) were randomized to participate in the Curves® (C) or 
Weight Watchers® (W) weight loss programs for 16-wks.   Participants in the C group 
(n=24) followed a 1,200 kcal/d diet for 1-wk; 1,500 kcal/d diet for 3 wks (~30%:45% 
CHO:PRO); and 2,000 kcals/d for 2-wks (45:30) and repeated this diet while 
participating in a supervised Curves® with Zumba program 3-d-wk.  Remaining subjects 
(n=27) followed the W point-based diet program, received weekly group counseling, and 
were encouraged to exercise.  Body composition, anthropometrics, resting energy 
expenditure (REE), lipid biomarkers, and hormone concentrations were assessed at 0, 4, 
10, and 16 weeks. Maximal cardiopulmonary exercise capacity and upper and lower 
body isotonic strength and endurance were assessed at 0 and 16 weeks. Data were 
analyzed using multivariate analysis of variance for repeated measures.  
 MANOVA analysis of body composition data revealed overall time (Wilks’ 
Lamda p=0.001) and time by diet effects (Wilks’ Lamda p=0.003).  Subjects in both 
groups lost a similar amount of total mass (C -2.4±2.0, -4.1±3.4, -5.1±3.9; W -2.3±2.3, -
4.5±3.0, -5.5±4.6 kg, p=0.78).  However, subjects in the C group tended to have a 
greater reduction in percent body fat  (C -3.3±5.2, -3.2±4.6, -4.7±5.4; W 0.6±6.7, -
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0.6±8.3, -1.4±8.1%, p=0.10) and body fat mass (C -3.9±5.5, -4.6±5.3, -6.4±5.9; W -
0.4±5.7, -2.1±6.7, -2.9±7.8 kg, p=0.09), while maintaining FFM (C 1.5±4.3, 0.52±3.7, 
1.3±4.0; W -1.8±5.4, -2.4±5.8, -2.5±5.1, p=0.01).  While both groups had increases 
cardiovascular fitness, the C group experienced improvements in upper body muscular 
endurance (C 1.4±3.9; W -1.2±2.4 repetitions, p=0.006).  Both groups experienced 
improvements in lipid biomarkers; however, only the C group experienced a moderate 
increase in HDL-c.  Results indicate that participants following the C program 
experienced more favorable changes in body composition and markers of fitness and 
health than participants in the W program. 
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CHAPTER I  
INTRODUCTION AND RATIONALE 
 
Background 
 Energy-dense diets and physical inactivity have led to a worldwide epidemic of 
obesity. The World Health Organization estimates that globally, 1.6 billion adults are 
overweight and at least 400 million adults are obese 1.  In the Unites States, current 
estimates are that 68% of US adults are overweight with 35.5% of women and 32.2% of 
men being characterized as obese 2. Obesity is a multi-factorial disorder that is strongly 
associated with comorbidities including dyslipidemia, hypertension, cardiovascular 
disease, stroke, pulmonary diseases, type II diabetes and cancer 3-11.  Obesity is also 
associated with diminished health related quality of life, altered psychological status and 
reduced sleep quality 12-14.  The medical cost of obesity in the United States may be as 
high as $147 billion annually 15.   
 Obesity manifests as a result of a multitude of factors.  In addition to over-
nutrition and physical inactivity, genetics, physiological factors and behavioral factors 
can all contribute to its manifestation. The physical and functional detriments caused by 
obesity, along with the direct and indirect costs of the disease, have caused much 
emphasis to be placed on elucidating ways to treat obesity and obesity related co-
morbidities. Some of the most studied non-pharmacological treatment strategies include: 
hypocaloric diets with a variety of macronutrient combinations, exercise, and behavioral 
interventions.   
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 Hypocaloric diets of varying macronutrient distribution have been shown to 
affect changes in metabolism and body composition and result in improved 
cardiometabolic risk factors such as blood glucose levels, insulin concentrations, blood 
lipids indices and blood pressure 16-19. A great deal of research has been conducted in 
order to ascertain the macronutrient nutrient composition that elicits optimal weight 
reduction and superior improvements in cardiometabolic health factors.  Diets composed 
of elevated protein combined with moderate amounts of carbohydrate and fat have been 
extensively studied and are often compared to diets high in carbohydrate in association 
with moderate intake of protein and fat.   
 Hypoenergenic diets in combination with elevated protein intake have been 
shown to result in increased satiety and increased thermogenesis 11, 20-22.  Furthermore, in 
several trials, a higher proportion of protein in combination with a reduction in total 
energy intake improved body composition, facilitated fat loss and improved body weight 
maintenance following weight loss when compared a high carbohydrate intake 23-25.  
However, other studies have failed to show a superior effect of elevated protein 
ingestion 26-28.  Investigations of whether elevated protein intake affects greater changes 
in markers of metabolic syndrome and cardiovascular risk factors have also had mixed 
results. Some investigations have shown a superior affect of elevated protein ingestion 
for the reduction of triacylglycerols and improved glucose homeostasis 23, 25, 29, while 
other have found no significant advantage 24, 27.   
 Exercise and exercise combined with caloric restriction have been shown to 
enhance weight loss, increase loss of body fat, and preserve lean body mass.  
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Additionally, exercise has been shown to improve cardiometabolic risk factors by 
affecting positive changes in serum lipids, blood pressure, and fasting plasma glucose 30. 
Moreover, exercise induced weight loss has also been associated with biopsychological 
changes including an improved satiety response to meals and improved appetite control 
31, 32.   
 Several investigations have explored the differential effects of combining 
exercise with hypocaloric diets high in protein or high in carbohydrate. Exercise in 
conjunction with hypocaloric high protein diets may lead to greater reductions in fat 
mass 33, 34, although not all studies have found a significant affect of elevated protein in 
comparison to high carbohydrate intake 35. Exercise combined with higher protein diets 
may lead to reductions in triacylglycerols 33, 34, whereas change in HDL-C, total 
cholesterol, and LDL-C have been equivocal when comparing the two diet types 33-35 
 In addition to hypocaloric diets and exercise interventions, behavioral and 
cognitive behavior therapies have been shown to facilitate weight loss 36, 37. Behavior 
modification is directed at changing behaviors that impede weight loss and derail weight 
maintenance.  Behavioral modification techniques include stimulus control, goal setting 
and self-monitoring 38.  Cognitive therapy strategies aim at identifying and modifying 
aversive thinking patterns 39. Cognitive-behavioral therapy can occur individually or in a 
group setting where treatment incorporates social support with information 
dissemination 40. 
 The alarming rise in the prevalence of obesity calls for the identification of 
weight loss programs that utilize proven weight loss strategies to affect change. 
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Watchers Watchers International, Inc. and Curves International, Inc. are two widely 
recognized commercial companies that provide weight management services that are 
based on scientifically validated principles.  Weight Watchers International, Inc. is a 
leading weight-management company with operations in more than 25 countries. 
Consumers bought $4 billion of Weight Watchers-branded products in 2008, and every 
week approximately 1.4 million people attend Weight Watchers meetings worldwide 41.  
In the Weight Watchers Momentum program, participants attend a weekly meeting 
conducted by leaders, who are Weight Watchers program graduates.  Meetings consist of 
group discussions and some individual interaction as members weigh in 42. Group 
discussions cover a variety of topics including physical activity, recipes, and behavior 
modification strategies 42.   
 In the Weight Watchers Momentum Program, participants are provided a diet 
plan based on the POINTs system.  The POINTS system assigns values to foods based 
on portion size, calories, fat and fiber content of foods 43. The majority of research 
investigating the efficacy of the Weight Watchers POINTS method has utilized the Pure 
POINTS system.  In a study conducted by Truby and colleagues, the Pure POINTS diet 
plan was shown to provide adequate macro- and micronutrient content with an estimated 
macronutrient breakdown of 19% Protein, 47% Carbohydrate, and 29% fat 44.  Several 
investigations have shown the efficacy of the Pure POINTS program for the reduction of 
body weight and improvement in cardiometabolic health markers 45-47.     
 Curves international is currently the largest fitness franchise in the world with 
nearly 10,000 locations in over 70 countries 48.  Participants in the Curves program 
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perform bi-directional, hydraulic resistance-training exercises interspersed with a low-
impact calisthenics exercise for 30-minutes, three times per week.  In conjunction with 
the exercise program, the Curves Fitness and Weight Management plan offers a higher 
protein (45% Protein, 30% Carbohydrate, 25% fat) or a higher carbohydrate (45% 
Carbohydrate, 30% Protein, 25% fat) dietary plan, which is followed in phases.  Phases 
include a 1,200 kcalorie phase (1 week) followed by a 1,500 phase (3 weeks) followed 
by a 2,000-2,500 calorie maintenance phase (2-4 weeks) 49.  The Curves Fitness and 
Weight Management Program is designed to promote and sustain weight loss in women 
while preserving fat free mass and resting energy expenditure.  
 Recent research has shown that the Curves exercise program, combined with 
cyclic weight reduction diets of variable macronutrient composition and caloric phase, is 
effective in reducing waist circumference, body mass, percent body fat, and waist and 
hip circumferences without associated reductions in resting energy expenditure 35, 50.  
The program has also been shown to impart improvements in cardiovascular and 
muscular fitness 35, 50, 51.  Furthermore, plasma leptin levels have been shown to be 
significantly decreased after 14 weeks of program participation 35. Interestingly, while 
one study found favorable but non-significant reductions in lipid panel indices after 14 
weeks, another revealed a reduction in serum triglycerides following 6 months of 
program participation 52.  Finally, participation in the curves program has been shown to 
improve quality of life and body image 35, 53.  Theoretically, participation in a structured 
diet and exercise program that includes resistance exercise may preserve FFM loss 
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during a weight loss program and thereby promote more optimal changes in body 
composition in comparison to a less structured diet and exercise program.   
Statement of the Problem 
Does the Curves Fitness and Weight Management plan greater improvements in 
body composition and markers of health and fitness than the Weight Watchers 
Momentum Plan in overweight and sedentary women aged 18-50 years? 
Purpose 
The purpose of this study was to determine whether following the Curves Fitness 
and Weight Management plan for 16 weeks promotes greater reductions in body weight, 
improvements in body composition and/or improvements in markers of fitness and 
health than following the Weight Watchers Momentum Plan for the same period. 
General Study Overview 
 This study was a 16 week study comparing two weight reduction protocols in 
women aged 18-50 years. Participants meeting physician approved criteria were matched 
for age and BMI and randomly assigned to either the Curves Fitness and Weight 
Management plan group or the Weight Watchers Momentum Plan group. Body 
composition, anthropometric measurements, resting energy expenditure (REE), serum 
clinical chemistry panels, whole blood counts and hormone concentrations, dietary 
intake and weekly physical activity, and quality of life were assessed at 0, 4, 6, 10, 12, 
and 16 weeks to determine differences in weight reduction program effects.  Maximal 
cardiopulmonary exercise capacity and upper and lower body isotonic strength were 
assessed at 0 and 16 weeks to ascertain chronic program effects.   
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Hypotheses 
Based on the aforementioned published research studies, the following hypotheses were 
evaluated:  
H1:  Participants in the Curves group (C) will experience significantly less loss in fat 
free mass than those in the Weight Watchers (W) group.  
H2:  Participants in the C group will experience statistically less loss in resting energy 
expenditure than those in the W group. 
H3: Participants in the C group will experience statistically higher increases in maximal 
cardiovascular capacity than those in the W group. 
H4: Participants in the C group will experience statistically higher increases in muscular 
strength and endurance than those in the W group. 
Null Hypotheses 
Previous research has not demonstrated the nature of the following relationships.  It was 
important to examine these relationships to check manipulations or confirm the lack of 
relationship.  Therefore the null hypotheses were stated in the following cases: 
H01: Participants in the C group will not experience statistically greater reductions in fat 
mass (FM) and percent body fat than those in the W group.  
H02:  Participants in the C group will not experience significantly greater reductions in 
resting cardiovascular parameters including resting heart rate and blood pressure than 
those in the W group.  
H03: Participants in the C group will not experience significantly greater changes in 
lipid variables than those in the W group.   
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H04: Participants in the C group will not experience statistically greater changes in HDL 
values than those in the W group.  
H05: Participants in the C group will not experience greater reductions in glucose 
variables (e.g., fasting glucose and insulin) than those in the W group.  
H06: Participants in the C group will not experience statistically greater changes in 
psychosocial status as measure via questionnaires than those in the W group.  
Delimitations 
The study was conducted within the following parameters: 
1. There were 100 sedentary overweight, female participants (BMI > 25) between the 
ages of 18-50 years recruited to participate in the study.  
2. Participants were recruited with flyers posted on campus, emails sent through the 
Texas A&M web, and through advertisements run in local newspapers and over local 
radio stations. 
3. Familiarizations and testing sessions were conducted in the Exercise and Sport 
Nutrition Laboratory (ESNL) at Texas A&M University. 
4. Participants were matched for age and BMI then randomly assigned to one of two 
treatment groups. 
5.  Participants had not consumed any nutritional supplements that may affect muscle 
mass or metabolism for at least three months prior to the start of the study. 
6.  Participants had not participated in an aerobic and/or anaerobic training program for 
three months prior to the start of the study. 
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Limitations 
1.  Participants were recruited from the Texas A&M University and the Bryan/College 
Station community from those who respond to advertisements for the study.  Therefore, 
the selection process was not truly random.  This may have affected the conclusions that 
can be applied to the general population. 
2. Participants in the Curves group were required to adhere to the Curves Weight 
Management Plan throughout the investigation.   
3.  Participants in the Curves group were required to adhere to the Curves fitness 
program consisting of one regular circuit workout and two Curves Zumba workouts each 
week throughout the investigation. 
4.  Participants in the Weight Watchers group were required to attend one Weight 
Watchers meeting each week throughout the investigation. 
5.  Participants in the Weight Watchers group were required to adhere to the Weight 
Watchers Momentum Program throughout the investigation. 
6. Participants were required to follow the Curves Fitness and Weight Management plan 
or the Weight Watchers Momentum plan within a free-living environment. 
7. Participants completed the Eating Satisfaction Survey, which has not been proven 
valid or reliable. 
8. There were innate limitations of the laboratory equipment that were used for data 
collection and analysis.  
9. There were innate limitations in the sensitivity of the technologies and protocols 
utilized to identify quantifiable changes in the criterion variables 
 10 
 
10.  Daily schedules of each participant and inherent circadian rhythms that exist for all 
humans as a result of slightly different testing times, stresses, etc., may have affected 
results. 
Assumptions 
1. Participants accurately answered the entrance criteria screening questions and the 
health and activity history forms. 
3. Participants followed the Curves Fitness and Weight Management plan or the Weight 
Watchers Momentum Plan as specified. 
2.  Participants were honest in completing questionnaires. 
4.  Participants were honest in completing food and activity logs. 
5.  Participants in the Weight Watchers group were honest regarding meeting attendance. 
6.  Participants in the Curves group followed intensity guidelines for all work outs. 
7. Participants were motivated and willing to maximally exert themselves during 
strength and maximal cardiopulmonary testing. 
8. Participants adhered to verbal and written instructions and refrained from exercise for 
48 hours prior to testing. 
9. Participants fasted for at least 12 hours prior to lab collection. 
10.  Participants reported any adverse events to lab staff. 
11. All laboratory equipment was calibrated and functioning properly for all testing 
sessions. 
12. The population, which the sample was drawn from, was normally distributed.  
13. The variability between the samples was approximately equal. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
Obesity Defined 
 The World Health Organization classifies overweight as between 25-29 kg/m2, 
moderately obese as > 30 kg/m2, and morbidly obese as > 40 kg/m2 54, 55.  Men and 
women who have a BMI > 30 are generally at higher risk for adverse health events than 
are those who are considered overweight or lean 56.  However, BMI does not distinguish 
between weight associated with muscle and weight associated with fat.  Other measures 
used to assess obesity include wait-to-hip ratio (WHR) and waist circumference (WC).  
A high WHR (> 1.0 in men and > 0.85 in women) is indicative of abdominal fat 
accumulation 57, 58 and may be a good predictor of health risk 59, 60.  However, this ratio 
can remain constant as individuals increase or decrease weight 61. Waist circumference 
provides information about body shape and the presence of central adiposity, as it 
correlates with abdominal fat mass 62, 63.  Men and women who have a waist 
circumference > 102 cm (> 40 in) or > 88 cm (> 35 in) respectively, may be at increased 
risk for metabolic disease 63-66.  In fact, waist circumference may be more useful for 
health assessment than either BMI or WHR alone or in combination 57, 61, 67-71.  
Interestingly, waist circumference and BMI are highly correlated (r values range form 
0.80-0.95) 62, 72.  An expert panel, organized by the National heart, Lung, and Blood 
Institute (NHLBI) has recommended that both BMI and WC be measured in clinical and 
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epidemiologic research in order to monitor the efficacy of weight-loss interventions and 
assess health risk in overweight and obese patients 64.   
Etiology of Obesity 
Genetics 
 Obesity represents a chronic imbalance between energy intake and energy 
expenditure.  A number of factors likely contribute to this energy imbalance. Firstly, 
genetic factors play a role. Investigations continue to elucidate heritable factors and their 
impact on the regulation of appetite, satiety and energy expenditure 73-76.  As of 2005, 
135 candidate genes have been linked with obesity-related phenotypes 77.  Genetic 
variations may contribute to individual variations in levels of fat oxidation, metabolic 
rate, spontaneous physical activity and sympathetic nervous system activity, which may 
all contribute to disparities in inter-individual weight gain 78. Furthermore, gene 
expression has been shown to be differentially regulated during calorie restriction and 
weight maintenance 79 . Interestingly, research has also shown that BMI is heritable 73, 80, 
81.  It has been estimated that genetic factors contribute between 30-70% to the 
development of obesity 82-84    
Excessive Intake 
 Weight gain may also occur secondary to excessive intake. Factors such as 
cognition, emotion and reward in addition to ubiquitous sources of highly palatable and 
relatively inexpensive food may contribute to excessive intake and lead to energy 
imbalance 36, 78. Developmental and epigenetic pathways to obesity have also been 
explored, where it is hypothesized that a nutritionally limited environment early in life 
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may lead to adaptive responses that increase the risk of developing obesity later on when 
living in an obesogenic environment 76.  Furthermore, there is growing evidence that 
hormone-mediated behavioral and neuronal activity contribute to appetite stimulation 
and increased food consumption 85.  
Physical Inactivity  
 Physical inactivity has been shown to contribute to energy imbalance.  On a 
population level, studies have demonstrated that decreased physical activity plays a 
prominent role in the increasing rates of obesity in increasingly sedentary populaces 86-90.  
A recent literature review examined available evidence for energy expenditure adapting 
to energy intake and vice versa. In a review of six studies where 54 subjects were 
overfed with 20-100% of weight maintenance intake for 14-65 days, an increase in 
energy intake did not result in an increase in energy expenditure through more body 
movement 91  Furthermore, in a study conducted by Stubbs and colleagues, reductions in 
physical activity to a more sedentary routine did not induce reductions in energy intake 
92. 
Hormones and other factors  
 In addition to genetics, excessive caloric intake, and inactivity, several hormone 
and secreted factors have been implicated in the etiology of obesity.  The gastrointestinal 
tract secretes hormones that affect appetite. Factors such as cholecystokinin (CCK), 
Glucagon-like peptide 1 (GLP-1), Oxyntomodulin, and peptide YY all contribute to 
satiety. One highly investigate orexigenic hormone, ghrelin, is synthesized mainly in the 
stomach but also exists endogenously in the hypothalamus 85, 93. It has been hypothesized 
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that ghrelin plays an important role in signaling energy insufficiency.  Ghrelin has been 
shown to stimulate appetite, promote food intake, and may facilitate weight gain 94-96.  
Ghrelin has also been implicated in insulin and glucose metabolism 97, 98.  
 Plasma ghrelin concentrations increase before meals and following food 
deprivation and decrease following feeding 99, 100.  Interestingly, fasting ghrelin levels 
are decreased in human obesity 101.  Additionally, obese individuals may demonstrate a 
reduced ghrelin post-prandial suppression, which may influence satiety and thus, 
reinforce obesity 102, 103.  Diet–induced weight loss is associated with an increase in 
fasting ghrelin. This increase in plasma ghrelin level with weight loss may be indicative 
of a long-term role in weight regulation in addition to the short term effects of ghrelin 
100.   
 Another highly investigated hormone is leptin. The hormone leptin is produced 
predominantly in adipose tissue. The concentration of leptin in adipose tissue and plasma 
parallels the mass of adipose tissue and plasma triglyceride content 99, 104.  It has been 
hypothesized that the major function of leptin is to signal CNS tracts regulating energy 
intake and expenditure that energy stores are below a critical level. This critical 
threshold may be determined by genetic, developmental, and/or metabolic circumstances 
99, 105.  Leptin may also work at the reward circuitry in the brain 85.  Obese individuals 
are typically hyperleptinemic. The failure of elevated leptin levels to suppress feeding 
and mediate weight loss has led to a suggestion of leptin resistance in obese individuals 
104.  Interestingly, leptin levels decrease with weight loss 106.  The resulting state of 
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relative leptin deficiency is characterized by leptin-mediated behavioral and neuronal 
activity responses that favor energy conservation and increased food consumption 85, 105.  
 Insulin, produced in the beta cell of the pancreas, is also a central player in 
systemic regulation of energy homeostasis. Insulin is secreted in response to meals and 
increases the storage of glycogen, fat and protein 99.  Insulin stimulates glucose uptake 
into skeletal muscle, inhibits hepatic gluconeogenesis, and decreases adipose tissue 
lipolysis and hepatic production of very-low density lipoproteins (VLDL).  Insulin 
signaling in the brain decreases appetite and prevents glucose production by the liver 
through neuronal signals from the hypothalamus 107.  Insulin, like leptin, also acts at the 
medial hypothalamus to provide negative feedback for food intake 85, 99, 106 and may 
work on the reward circuitry of the brain 85. Insulin resistance leads to the release of free 
fatty acids from adipose tissue, increased hepatic production of VLDLs, and decreased 
HDL-c 107. 
Relationship of Energy Expenditure to Obesity 
 Researchers continue to investigate the relationship between energy expenditure 
and weight gain.  Total energy expenditure (TEE) is the sum of resting energy 
expenditure (REE: cardiorespiratory work and the work of maintaining transmembrane 
ion gradients at rest; ~60% of TEE), the thermic effect of feeding (the work of digestion; 
~5-10%) and non-resting energy expenditure (NREE, energy expended in physical 
activity above resting; ~30-40% of TEE) 108. On an absolute basis, REE tends to be 
higher in obese individuals. However, when adjusted for fat-free mass, REE values for 
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obese and non-obese individuals tend to be analogous and do not predict future weight 
gain 89, 109, 110.  
 Interestingly, some investigations have found total energy expenditure to be 
disproportionately reduced following caloric restriction induced weight reduction 111, 112. 
A review article by Rosenbaum et al. 108 surmised that maintenance of a 10% or greater 
reduction in body weight may be accompanied by a ~20-25% decline in 24-h energy 
expenditure. This decrease would be below that predicted solely on alterations in fat and 
lean mass.  Thus, a formerly obese individual would require a ~300 to 400 kcal per day 
less to maintain the same body weight as an individual of the same body weight and 
composition who has never been obese. A meta-analysis of 12 studies found that high 
rates of weight gain in formerly obese individual were related to a 3-5% lower RMR in 
comparison to healthy weight controls 113.  In contrast, other studies have failed to find 
significant changes in RMR following weight loss 114, 115. The variability between study 
results may be due to factors such as changes in subject fitness, time spent performing 
physical activity or duration of weight stability before and after weight loss 108.  Since 
changes in the thermic effect of feeding are negligible following weight loss 111, and 
potential changes in RMR are relatively modest, the majority of change to total energy 
expenditure following weight reduction may be secondary to reductions in NREE 
expenditure. One hypothesis is that disproportionate reductions in energy expenditure 
following weight loss may be largely due to increased skeletal muscle work efficiency 
105, 116, 117. 
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Common Consequences of Obesity 
Metabolic Syndrome 
 Metabolic syndrome is a cluster of interrelated risk factors that indicate an 
increased risk for type 2 diabetes mellitus (DM) and coronary artery disease (CAD) 118.  
Metabolic syndrome is characterized by abdominal obesity, insulin resistance and 
glucose intolerance, elevated blood pressure, atherogenic dyslipidemia, and a 
prothrombic as well as proinflammatory state 119-121.  According to the National 
Cholesterol Education Program Adult Treatment Panel (NCEP ATP III), a diagnosis of 
metabolic syndrome is established when 3 of the following 5 criteria present: fasting 
glucose > 6.1 mmol/l (> 110 mg/dl); waist circumference > 102 cm (> 40 in) in men or > 
88 cm (> 35 in) in women;  triglycerides (TG) > 1.7 mmol/l (> 150 mg/dl); Blood 
pressure (BP) > 130/85 mmHg; high-density lipoprotein cholesterol (HDL-c) < 1.04 
mmol/l (< 40 mg/dl in men, < 1.29 mmol/l (< 50mg/dl) in women 120. Insulin resistance 
is a pervasive metabolic complication associated with obesity and metabolic syndrome.  
Individuals with insulin resistance tend to have impaired fasting plasma glucose levels, 
which increase the prevalence of more atherogenic, small dense low density lipoprotein 
(LDL-c) particles and a postprandial accumulation of TG-rich remnant lipoproteins 122.  
Endothelial dysfunction associated with insulin resistance can lead to hypertension 107, 
123.  
 The etiology of insulin resistance continues to be elucidated.  Insulin resistance 
may be mediated in part by elevated circulating free fatty acids derived from adipocytes, 
adipocyte-derived cytokine actions, a reduced capacity of skeletal muscle to oxidize 
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fatty acids, elevated impairments in mitochondrial function, or inflammation associated 
with chronic over-nutrition 79, 107, 124, 125. Weight loss via caloric restriction is known to 
attenuate or reverse insulin resistance 126, 127. Caloric restriction combined with exercise 
has also been shown to improve insulin sensitivity 124, 128-131. Reduced insulin resistance 
after weight loss may be primarily mediated by a reduction in fatty acid mobilization 124. 
 As previously mentioned, insulin resistance is associated with an atherogenic 
lipoprotein profile. The typical dyslipidemic profile of metabolic syndrome is 
characterized by elevated triglycerides, a low level of HDL-c, and a preponderance of 
small, dense LDL-c particles.  Plasma levels of LCD-c may be normal or modestly 
elevated 119, 132, 133.  Atherogenic dyslipidemia has been shown to be associated with an 
increased risk of cardiovascular disease 134.   Furthermore, a large meta-analysis of 37 
studies (172,573 patients) found that the presence of metabolic syndrome almost doubles 
the risk of cardiovascular events and death (odds ratio, 1.78; confidence interval 1.58-
2.00) 135.  
Diminished Quality of Life 
 Obesity is not only characterized by significant clinical repercussions, but is also 
has negative effects on levels of independence, psychological well-being and overall 
quality of life 136, 137.  Disability may be defined as a restriction in ability to perform an 
activity in any domain of life 138.  One tool extensively used for the assessment of health 
related quality of life (HRQL) is the Medical Outcome Survey Short-Form 36 (SF-36).  
This instrument measures the extent of HRQL in both physical and mental domains.  
The questionnaire consists of 36 multiple choice questions measuring 8 different 
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domains; 4 in the area of physical health (physical functioning, role limitation-physical, 
bodily pain, general health) and 4 in the area of mental health (role limitation-emotional, 
vitality, mental health, and social functioning) 139-141.  Increasing BMI is associated with 
progressively impaired HRQL, with physical status affected more profoundly than 
mental health 142-144. Furthermore, moderate weight loss is associated with improved 
health related quality of life 142, 145. 
Non-pharmacological Treatment of Obesity 
Dietary Intervention 
 A great deal of research has been conducted in order to ascertain the 
macronutrient nutrient composition that elicits optimal weight reduction and superior 
improvements in cardiometabolic health factors. Very low carbohydrate (CHO) (< 20-50 
g CHO/d) ketogenic diets, diets high in carbohydrate combined with low fat and 
moderate protein, and diets containing elevated protein combined with moderate 
amounts of carbohydrate and fat have been extensively investigated 146.  Several studies 
have shown that very low-carbohydrate diets can produce significantly greater weight 
loss than isocaloric low-fat diets and improve markers of metabolic syndrome and 
cardiovascular risk factors in both healthy persons and in persons with type 2 diabetes 
146-152. In a systematic review comparing low-carbohydrate/high protein diets (< 20-60 g 
CHO/d) to low-fat/high-carbohydrate diets (fat < 30% daily intake) in 1,222 adults (BMI 
> 28 kg/m2), low-carbohydrate/high protein diets were more effective at 6 months and as 
effective if not more effective in reducing weight and cardiovascular disease risk factors 
at 1 year. The review also revealed a higher attrition rate for the low fat/high 
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carbohydrate groups versus the low carbohydrate groups suggesting a participant 
preference for the later 153.  Though very low carbohydrate diets have been shown to be 
efficacious for weight reduction, they restrict fruit and vegetable intake.  This may lead 
to vitamin and mineral deficiencies or constipation if the diet if followed for a prolonged 
period.  
 Diets with elevated protein content combined with moderate levels of fat and 
carbohydrate have also been extensively studied.  The definition of a high protein diet 
varies considerably in the literature, with intakes ranging from 27-68% of daily energy 
intake or 90.5 to 284 g/d in absolute amounts.  Most investigations have compared a 
high protein diet to a diet high in carbohydrate and low in fat.  In a study by Noakes et 
al. 154, 100 women (mean+SD: age 49+9 years; BMI 32+6  kg/m2) followed either a high 
protein diet (34% protein, 46% CHO, 20% fat) or a high carbohydrate diet (17% protein, 
64% CHO, 20% fat) for 12 weeks. There were no significant diet composition effects on 
fasting LDL-c, HDL-c, glucose, insulin, FFA, and C-reactive protein concentrations. 
However, triacylglycerol (TAG) concentrations decreased more with the high protein 
diet. Furthermore, subjects with high serum TAG levels (> 1.5 mmol/L) had 
significantly greater reductions in fat mass and TAG concentrations following the higher 
protein diet.    
 In a study conducted by Layman and associates 23, 29, women (n=24; 45 to 56 
years; BMI > 26 kg/m2) were assigned to either a carbohydrate group consuming a 
isoenergetic diet with a CHO/protein ratio of 3.5 (68 g protein or ~.8 g/kg/d) or a protein 
group with CHO/protein ratio of 1.5 (125 g protein/d or ~1.6 g/kg/d) for 10 weeks. Both 
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diets had similar amounts of fat (~ 50 g/d or 30% energy intake).  Subjects in the protein 
group had a significantly higher loss of fat/lean tissue compared to the carbohydrate 
group. The high protein group had significant reductions in triacylglycerol levels and the 
ratio of TAG/HDL cholesterol, whereas both groups had significant reductions in total 
cholesterol levels. In contrast to the protein group, the carbohydrate group had higher 
insulin responses to meals and postprandial hypoglycemia.  Thus, the isocaloric higher 
protein diet had positive effects on body composition, blood lipids, glucose homeostasis 
and satiety.  
 Due and associates 24 studied 50 overweight and obese subjects (age 19-55; BMI 
26-35 kg/m2] who followed either a high protein diet (25% protein, 45% CHO, 30% fat) 
or a “medium protein” diet (12% protein, 58% CHO, 30% fat) for 6 months followed by 
a 6-12 month dietary counseling period and a subsequent 24 month follow-up. The high 
protein group had a significantly greater weight loss and fat mass reduction at 6 months, 
while at 12 months there was no difference between groups.  The high protein group did 
have a 10% greater reduction in intra-abdominal adipose tissue than the medium protein 
group at 12 months.  Both groups tended to maintain their 12 month weight loss at 24 
months, although 50% of subjects were lost to follow-up.  There were no differences 
between groups in serum markers of metabolic syndrome and cardiovascular risk 
factors. 
 In an investigation conducted by Skov et al. 25, 60 healthy, overweight and obese 
subjects followed either a high-carbohydrate (12% protein, 58% CHO, 30% fat) or high 
protein (25% protein, 45% CHO, 30% fat) ad libitum diet for 6 months. There was a 
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significantly greater reduction in weight, total body fat, and intra-abdominal adipose 
tissue in the high protein group compared to the high-carbohydrate group, whereas the 
control group experienced no body composition changes.  The greater weight loss (8.9 
vv. 5.1 kg) and fat loss (7.6 vs. 4.3 kg) most likely occurred secondary to lower energy 
intake [5.0 (1,194 kcals) vs. 6.2 Mj/d (1,480 kcals)] in the high protein group.  
Additionally, more subjects lost > 10 kg in the high protein group. Total cholesterol and 
HDL-C decreased in both diet intervention groups with no group differences, while no 
significant changes were observed in the control group.  The high protein diet had a 
significantly greater reduction in fasting plasma TG and free fatty acids than the high 
carbohydrate group.  
 Sacks et al. 26assigned 645 subjects [mean+SD; age 52+9 years; BMI 33+4 
(kg/m2)] to either a low-fat, average protein diet (15% protein, 65% CHO, 20% fat) to a 
low-fat, high protein diet (25% protein, 55% CHO, 20% fat), a high-fat average protein 
diet (15% protein, 45% CHO, 40% fat) or a high-fat high protein diet (25% protein, 35% 
CHO, 40% fat).  Reductions in body weight, waist circumference, blood pressure, and 
serum triglyceride levels did not differ significantly between the 4 groups at either 6 or 
12 months.  All diets except the one with the highest carbohydrate content (low-fat, 
average protein diet) decreased fasting serum insulin levels.  Additionally, at two years, 
the low-fat diets decreased LDL-C significantly more than the high fat diets. The 
investigators concluded that macronutrient composition of diets is less important than 
calories for weight loss over 2 years 26.  
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 Few investigations have studied the effects of diets where > 40% of calories are 
derived from protein. In a 4 week study conducted by Luscombe-Marsh and colleagues 
27, a low-fat, high protein diet (40% protein, 30 % CHO, 30% fat) was compared to a 
high–fat standard protein diet (20% protein, 30% CHO, 50% fat) in adults (n=57; mean 
BMI 33.8+0.9 kg/m2). There were no differences between groups in weight loss, fat loss, 
REE, or in glucose and insulin response.     
Advantages of Diets High in Protein 
 Proteins have been shown to be the most satiating macronutrient 20, 21, 155-159.  It 
has been hypothesized that protein-induced satiety is somehow related to relatively high 
increases in concentrations of anorexigenic hormones such as Glucagon-like peptide-1 
(GLP-1), peptide YY (PYY), and Cholecystokinin (CCK), or decreases in orexigenic 
hormones such as Ghrelin. Some investigations have demonstrated significant changes 
in hormone concentration after consumption of a high protein meal for GLP-1 160, 161, 
PYY 162, and CCK 161, while others have not 163.  Changes in GLP-1 may be dependent 
on the presence of carbohydrate, which stimulates GLP-1 release 21, 164.  Changes in 
hormones may also be dependent on the composition of exogenous peptides contained in 
diets 161 and the time frame of over which a diet is consumed 155. Additional 
investigation is needed as changes in anorexigenic and orexigenc hormones have 
inconsistent relationships with satiety 161, 163.   
 High protein foods have also been shown to have a higher thermogenic effect 
than foods higher in other macronutrients 160, 165-168. Protein has a gross energy value of 
22-25 kJ · g -1 and a net metabolizable energy of 13 kJ · g -1, which is lower than either 
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fat or carbohydrate 22, 169. Several trials have investigated the effect of diet composition 
on the thermic effect of food or diet-induced energy expenditure, a component of daily 
energy expenditure.  High protein diets have consistently been shown to induce higher 
energy expenditure than diets higher in other macronutrients 170-172.   
 While there is a general consensus that protein increases satiety and stimulates 
dietary–induced thermogenesis above other macronutrients, the effect of elevated protein 
intake on body composition continues to be investigated. Several studies have shown 
that higher protein diets may increase total weight loss and increase the percentage of fat 
loss 23-25, while others have not 26-28 
Exercise Intervention 
 Exercise and exercise combined with caloric restriction have been shown to 
enhance weight loss and improve cardiometabolic risk factors.  A Cochrane review 
examined 43 studies that included a total of 3,476 participants and found that exercise 
resulted in small weight losses across studies when compared with no exercise. Exercise 
combined with diet resulted in greater mean weight reduction than diet alone (-1.0 kg, 
95% CI-1.3 to -0.7).  Furthermore, increasing exercise intensity resulted in an increase in 
the magnitude of weight loss (-1.5 kg, 95% CI -2.3 to -0.7).  Exercise alone resulted in 
significant reductions in triglycerides (-0.2 mmol/L; 95% CI -0.3 to -0.1), diastolic blood 
pressure (-2 mmHg; 95% CI -4 to -1), and fasting glucose (-0.2 mmol/L; 95% CI -0.3 to 
-0.1) 30.  Exercise induced weight loss has also been associated with physiological and 
biopsychological changes including an improved satiety response to meals and improved 
sensitivity to appetite control systems leading to reductions in hunger 31, 32. 
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 The International Association for the Study of Obesity (AISO) has published a 
consensus statement on physical activity recommendations for obesity prevention and 
weight maintenance.  For prevention, moderate intensity activity of approximately 45-60 
minutes per day may be required to prevent the transition to overweight or obesity. In 
order to maintain significant weight loss, 60-90 min of moderate intensity physical 
activity may be required daily 173.  
High Protein Diet Combined with Exercise  
 Investigations combining high protein diets with exercise are surprisingly rare. In 
a study conducted by Layman and associates 33, 48 women (aged 40-56y; BMI > 26 
kg/m2) were assigned to either a high protein diet (30% protein, 40% CHO, 30% fat; 
carbohydrate/protein ratio < 1.5) with lifestyle activity group (n=12), a high protein diet 
combined with exercise group (n=12), a high carbohydrate diet (15% protein, 55% CHO, 
30% fat; carbohydrate/protein ratio > 3.5) with lifestyle activity group (n=12), or a low 
high carbohydrate diet combined with exercise group (n=12) for 4 months.  The high 
protein and high carbohydrate diet plus lifestyle activity groups walked for 30 minutes 5 
d/wk.  The “exercise” groups participated in walking for 30 minutes 5 d/wk combined 
with resistance training 2 d/wk (30 minutes of stretching and resistance exercise utilizing 
weight machines). All groups experience significant weight loss, however, weight 
changes were larger in the groups consuming the higher-protein diet (p=0.05). Exercise 
increased loss of body fat and preserved lean mass. Additionally, subjects in the high 
protein diet groups had greater reductions in triacylglycerol and maintained higher 
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concentrations of HDL-c, whereas, subjects in the high carbohydrate diet groups had 
greater reductions in total cholesterol and LDL-c. 
 Meckling and colleagues 34 randomized 44 overweight women (aged 20-62 
years; BMI 25-30 kg/m2) into a high protein diet group (n=10; protein/CHO ratio 1:1; 
30% fat), a high protein combined with exercise group (n=14), a high carbohydrate 
group (n=8; protein/CHO ratio 1:3; 30% fat), or a high carbohydrate diet combined with 
exercise group (n=11) for 12 weeks.  Exercise consisted of a supervised circuit training 
program 3 d/week. All groups experienced weight loss: -2.1 kg for the high carbohydrate 
group, -4.0 kg for the high carbohydrate combined with exercise group, -4.6 kg for the 
high protein group and -7.0 kg for the high protein/exercise group, with significant 
differences between all groups (p=0.05).  The groups consuming a high protein diet had 
greater reductions in fat mass (determined by BIA) than those groups consuming a diet 
high in carbohydrate. The high protein group had a significant decrease in HDL-c, the 
high protein/exercise group had decreases in triglycerides, and both the high protein and 
high carbohydrate/exercise groups had decreases in total cholesterol.  
Behavior Modification and Cognitive Therapy 
 Behavior modification is directed at changing behaviors that impede weight loss 
and disrupt weight maintenance.  Behavioral modification techniques include stimulus 
control, goal setting and self-monitoring 38.  Cognitive therapy strategies aim at 
identifying and modifying aversive thinking patterns and mood states in order to 
facilitate weight loss 39. Cognitive-behavioral therapy can occur individually or in a 
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group setting where treatment incorporates social support, problem solving, information 
dissemination, and encouragement to facilitate weight loss 40.    
 Behavioral and combined cognitive-behavioral therapies have been shown to 
facilitate weight loss. A Cochrane review of 36 studies and a total of 3,495 participants 
examined psychological interventions for the treatment of overweight or obese patients. 
Behavioral therapy resulted in greater weight reductions than placebo when assessed as a 
stand-alone weight-loss strategy (mean weight loss -2.5 kg, 95% CI -1.7 to -3.3).  
Furthermore, cognitive behavioral therapy combined with diet and exercise increased 
weight loss by 4.9 kg compared with diet and exercise alone (mean weight loss -4.5 kg, 
95% CI -7.3 to -2.4) 36. A systematic review conducted by brown and colleagues 37 also 
demonstrated that behavioral therapy techniques combined with diet and/or exercise can 
enhance weight loss. 
Relevant Weight Watchers Research 
 The majority of Weight Watchers research has been conducted on the Weight 
Watcher’s Pure POINTs program.  In an investigation conducted by Heshka and 
colleagues 47, the Weight Watchers Pure POINTs program was compared to a self-help 
weight reduction program. Subjects enrolled in the Weight Watchers Pure POINTs 
program (n=171) had significantly greater reductions in body weight [mean+SD; -4.8+ 
5.6 vs. -1.4+4.7 kg; p=0.001), body mass index (-1.7 + 1.9 vs. -0.5 + 1.6 kg ·m-2: 
P=0.001), waist circumference (-4.3 + 10.5 vs. -0.7+12.7 cm: p=0.05), and fat mass (-3.8 
+7.0 vs. -1.5+7.6 kg: p=0.05) than the those in the self-help group (n=168) after 26 
weeks of program participation.  In a study comparing Weight Watchers to 3 other 
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commercially available weight loss programs available in the UK, subjects enrolled in 
the Weight Watchers Pure POINTs program for 6 months (n=16) experienced reductions 
in plasma LDL cholesterol (-12.2%: p= 0.01), and plasma triacylglycerol levels (-22.6%: 
p=0.01), in addition to a 9.0+5.6% reduction in body weight 45, 46.   
Relevant Curves Research 
 In a study conducted by Kersick and colleagues 35, 161 obese, sedentary, 
premenstrual women (age 38.5+8.5 years; BMI 34.9±6.3 kg/m2) were assigned to either 
a no diet control group (CON) (n=7), a no diet exercise group (ND) (n=17), a high 
energy, high carbohydrate low protein diet group (HED) (n=11; 2,600 kcalories; 15% 
protein, 55% CHO, 30% fat), a very low carbohydrate, high protein diet group (VLCHP) 
(n=48; 63% protein; 7% CHO, 30% fat), a low carbohydrate, moderate protein diet 
group (LCMP) (n=37; 20% protein; 50% CHO, 30% fat), or a high carbohydrate, low 
protein diet group (HCLP) (n=41; 15% protein; 55% CHO, 30% fat) for 14 weeks.  The 
HED, VLCHP, LCMP and HCLP groups ingested 1,200 kcalories for 2 weeks, 1,600 
kcalories for 8 weeks, and 2,600 kcalories for the remaining 4 weeks of the study. All 
groups except the control group performed circuit training for 30 minutes 3 times 
weekly. All groups excluding the CON group had significant reductions in waist 
circumference. The VLCHP, LCHP and LCMP groups had similar significant reductions 
in body mass (P < 0.05 – 0.001) in comparison to other groups. The VLCHP, LCMP and 
HCLP groups had significantly greater body fat percentage reductions when compared to 
the other groups. All exercise groups had analogous gains in muscular fitness (P < 0.05).  
Favorable but non-significant reductions occurred in lipid panels, glucose and HOMA-
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IR levels, whereas, leptin levels significantly decrease in all groups excluding the CON 
group. The exercise groups also experienced significant improvements in quality of life 
and body image indices.  Finally, resting energy expenditure lowered during the 1,200 
kcalorie phase, but returned to baseline levels or above during the 1,600 kcalorie phase 
and further increased during the 2,600 kcalorie diet phase for the VLCHP, LCMP, and 
HCLP groups.  
 In another investigation, 43 overweight sedentary women (age 35+8 yrs; BMI 
33±6 kg/m2) were assigned to either a high carbohydrate diet (n=23; 30% protein, 45% 
CHO, 25% fat) or to a high protein diet (n=20; 45% protein, 30% CHO, 25% fat).  Both 
groups ingested 1,200 kcalories for 1 week, 1,500 kcalories for 3 weeks, and 2,200 
kcalories for the remaining 4 weeks. This cycle was repeated for the duration of the 
study. Both groups performed circuit training for 30 minutes 3 times weekly and walked 
briskly for 30 minutes 3 days/week. There were no significant differences between the 
two groups. Overall, training combined with caloric restriction resulted in significant 
reductions in body mass, fat mass, percent body fat waist and hip circumferences, resting 
systolic blood pressure, and serum triglyceride levels. Favorable but non-significant 
reductions occurred in total cholesterol and LDL-c levels.  There were no significant 
changes in glucose or HDL-c levels. Absolute REE values modestly decreased over 
time, but were not significantly changed when weight loss was accounted for. Training 
also induced gains in cardiopulmonary fitness and muscular strength. Furthermore, 
training and dieting improved quality of life 50-53. 
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CHAPTER III 
METHODS 
 
Participants 
 A total of 149 sedentary overweight females (BMI > 25) between the ages of 18 
and 50 years were recruited to participate in this study. Of these, 127 met phone 
interview entrance criteria and were invited to attend familiarizations sessions.  Subjects 
had not been involved in an anaerobic or aerobic exercise training program for at least 
the last three months and had not taken ergogenic levels of nutritional supplements that 
could affect muscle mass or anaerobic exercise capacity (i.e. creatine, ergogenic levels 
of caffeine, HMB, etc.), anabolic/catabolic hormone levels (i.e. androstenedione, 
DHEA), or weight loss (i.e. ephedra, thermogenics) for at least three months prior to the 
start of the study. Participants with uncontrolled metabolic disorders, known electrolyte 
abnormalities, heart disease, arrhythmias, diabetes, or thyroid disease; a history of 
hypertension, hepatorenal, musculoskeletal, autoimmune, or neurological disease were 
not allowed to participate in the study. Participants with a controlled medical condition 
had their physicians complete and sign the physician’s consent form prior to 
participation in the study.  Subjects meeting eligibility criteria were informed of the 
study requirements and signed an informed consent statement in compliance with the 
Human Subjects Guidelines of the Texas A&M University and the American College of 
Sports Medicine.  
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Study Site 
 Familiarization and testing in addition to Curves circuit workouts took place in 
the Exercise and Sport Nutrition Laboratory in the Department of Health and 
Kinesiology at Texas A&M University in College Station, Texas.  
Experimental Design 
 Table 1 shows the general research design and time course for assessments. The 
study included a baseline testing session followed by 5 additional testing sessions.  
Exercise testing occurred at the baseline and final testing session only.  During testing 
sessions 2 through 5, only resting tests were conducted. The independent variable was 
weight loss program intervention. Dependent variables included: estimated dietary 
energy intake; estimated weekly physical activity (International Physical Activity 
Questionnaire – IPAQ); hip and waist anthropometric measurements; resting energy 
expenditure (REE); body composition; fasting clinical blood profiles (cholesterol, 
glucose, liver enzymes, red cells, white cells, insulin, leptin); maximal cardiopulmonary 
exercise capacity (peak VO2); maximum repetition maximum (1RM) and 80% 1RM  
Isotonic testing; standardized quality of life (SF-36); and eating satisfaction inventory.  
Familiarization Session 
 Participants who expressed interest in this study were interviewed on the phone 
to determine whether they qualified to participate.  Participants who met the eligibility 
criteria were invited to attend a familiarization session.  During this session, participants 
received written and verbal explanation of the study protocol and design, testing 
procedures and equipment, and blood procedures that would occur throughout the study. 
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A registered dietitian provided instruction on accurate dietary record completion and 
estimation of portion sizes. Participant height and weight were attained.  Participants 
then signed informed consent statements and completed personal and medical histories. 
Participants with controlled metabolic disorders were required to obtain medical  
clearance from their personal physician prior to participating in the study.  Participants 
 
Table 1. Overview of Research Design and Testing Schedule 
Familiarization  
 
Baseline 
(T1) 
4 Weeks 
(T2) 
6 Weeks 
(T3) 
10 Weeks 
(T4) 
12 Weeks 
(T5) 
16 Weeks 
(T6) 
 
Complete 
Paperwork 
 
Review 
Medical 
history 
 
Randomized 
assignment 
 
 
 
Diet Record  
Review 
 
IPAQa 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting Energy 
Expenditure 
 
Resting BPb and 
HRc 
 
DEXAd Scan 
 
Fasting Blood  
 
Maximal 
Cardiopulmonary 
Exercise Test 
 
1RMe and 80% 
1RM  Isotonic 
Leg Press and 
Bench Press 
Measures  
 
Survey 
Completionf 
 
 
Diet Record  
Review 
 
IPAQ 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
DEXAc Scan 
 
Fasting Blood  
 
Survey 
Completion 
 
Diet Record  
Review 
 
IPAQ 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
DEXAc Scan 
 
Fasting Blood  
 
Survey 
Completion 
 
 
Diet Record  
Review 
 
IPAQ 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
DEXAc Scan 
 
Fasting Blood  
 
Survey 
Completion 
 
 
Diet Record  
Review 
 
IPAQ 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting 
Energy 
Expenditure 
 
Resting BPa 
and HRb 
 
DEXAc Scan 
 
Fasting Blood  
 
Survey 
Completion 
 
 
Diet Record 
Review 
 
IPAQ 
 
Body Weight 
 
Hip and Waist 
Measurements 
 
Resting Energy 
Expenditure 
 
Resting BP and 
HR 
 
DEXA Scan 
 
Fasting Blood  
 
Maximal 
Cardiopulmonary 
Exercise Test 
 
1RM and 80% 
1RM  Isotonic 
Leg Press and 
Bench Press 
Measures  
 
Survey 
Completion 
aInternational Physical Activity Questionnaire 
bBlood Pressure 
cHeat Rate 
dDual Energy X-ray Absorptiometry 
eRepetition Maximum 
fStandardized quality of life (SF-36) and eating satisfaction inventory  
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were then matched according to body mass index (BMI) and age into either the Curves 
(C) group or the Weight Watchers (W) group. 
Curves Fitness and Weight Management Plan 
 Participants in the C group followed the Curves Fitness and Weight Management 
Plan.  In concurrence with this plan, subjects followed the Phase 1 higher protein weight 
loss diet (1,200 kcals/day) for one week and the phase 2 high protein weight loss diet 
(1,500 kcals/day) for 3 weeks.  Phase 3 consisted of a metabolic recovery phase. During 
phase 3, subjects followed a 2,000-2,500 kcals/d higher protein diet for two weeks.  If 
subjects had a weight increase of 3 pounds during phase 3, they were instructed to return 
to Phase 1 for 2-3 days until their weight returned back down. The three dietary phases 
were cycled in this manner over the course of 16 weeks. A registered dietitian reviewed 
the Curves high protein diet (HPD) and exercise plan with subjects and provided them 
with the “Curves Fitness and Weight Management Plan” 49, “The Curves Food & 
Exercise Diary” 174, and “Curves Essentials 2 go” dietary supplements. Participants were 
encouraged to consume two multivitamins, 800mg of calcium, and 520mg of Omega-3 
fatty acids daily. The dietitian also met with subjects weekly throughout the study to 
discuss any dietary challenges or concerns. The Curves Fitness and Weight Management 
Plan dietary intervention protocol is delineated in Table 2. 
 The Curves physical training protocol included one regular curves circuit work 
out and two Curves Zumba workouts each week for 16 weeks, while maintaining a 
greater than 80% compliance record.  Attendance was recorded at each workout session  
in order to monitor compliance. The Curves circuit consisted of 13 bi-directional 
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hydraulic resistance exercise machines that worked all major muscle groups.  During the 
Curves circuit workout, subjects were instructed to complete as many repetitions as 
Table 2. Curves Fitness and Weight Management Dietary Plan 
 
 
Dietary Phase 
 
 
Kcalories 
 
 
Group 
 
 
Macronutrient 
 
 
g/d 
 
 
Kcals/d 
 
Percentage  
Daily Diet (%) 
 
Phase 1 
(1 Week) 
 
1,200 kcals/da 
 
HPDb + Exercise 
 
PROc  
CHOd 
FAT  
 
135  
90  
33   
 
 
 
540  
360  
300   
 
 
 
45  
30  
25   
 
 
 
Phase 2 
(3 Weeks) 
 
1,500 kcals/d 
 
HPD + Exercis 
 
PRO  
CHO 
FAT  
 
169  
113 
42   
 
675  
450  
375   
 
45  
30  
25   
 
 
Phase 3 
(2 weeks) 
 
2,000-2,500 kcals/d 
 
14 Day Metabolic 
Recovery 
 
* Subjects can 
adjust caloric intake 
as needed to 
maintain weight 
(e.g., 2,000 – 2,500 
kcals/d) with 2,200 
kcals/d given as an 
example starting 
diet. 
 
* If subjects gain 3 
lbs during the 
metabolic recovery 
period, they  will 
follow the 1,200 
kcal/d diet for 2-3 
days to adjust 
weight back down 
 
 
HPD + Exercise 
 
 
 
  
 
 
PRO  
CHO 
FAT  
 
  
 
 
165 
248  
61   
 
 
 
660 
990  
550  
 
  
 
 
30  
45  
25   
 
 
aKcalories per day 
bHigh protein diet. 
cProtein 
dCarbohydrate 
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possible during a 30 second time period on each resistance machine. Between machines, 
subjects performed floor-based aerobic exercises designed to maintain an elevated heart 
rate. Subjects performed the entire circuit twice during the 26 minute regular circuit 
workout.  During the Curves Zumba workout, subjects performed 1 minute of Zumba 
dance moves in-between 1 minute of resistance exercise on each machine.  All Zumba 
classes were taught by a certified Zumba instructor and all training sessions were 
monitored by trained fitness instructors.  Subjects were assisted with self-monitoring of 
heart rate in order to maintain an exercise heart rate between 60-80% of target heart rate 
using age-predicted maximal heart rate (220-age). Subjects also performed 5 minutes of 
whole body stretching after all circuit workouts.  In addition to circuit training, subjects 
were encouraged to walk for 30 minutes at a brisk pace [60-80% of heart rate reserve 
(maximum HR- resting HR)] on most days of the week. The Curves circuit was located 
in the Exercise and Sports Nutrition Laboratory.   
Weight Watchers Momentum Program 
 Participants assigned to the W group took part in the Weight Watchers 
Momentum Program and were signed up for a Weight Watchers monthly pass 
subscription.  Subjects were required to attend 1 meeting each week with an 80% 
compliance record.  Subjects emailed the study coordinator each time they attended a 
meeting. Meetings consisted of group discussions and some individual interaction as 
members weighed in. The core program material was delivered over ten weeks and 
included: food plans based on the POINTs system, exercise recommendations, strategies 
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for dealing with hunger, successful habits, strategies for eating out, tracking intake and 
activity, eating with others, recipes, workout variation, and plateaus.  
 The momentum eating plan revolved around the POINTS system.  On the 
POINTS plan, subjects were assigned a daily POINTS target that was based on weight, 
height, age, and activity level.  Subjects were also allowed additional POINTS each 
week, which could be utilized as needed.  The POINTS values assigned to foods were 
based on portion size, calories, fat and fiber content.  POINTS values were also provided 
for activity, and were based on weight, time, and intensity. Subjects were encouraged to 
track their intake of foods and beverages. The Weight Watchers Momentum program 
also encouraged subjects to perform 30 minutes of activity on most days of the week.  
Study participants were encouraged to purchase the Weight Watchers 2010 Basic 
Member Kit, which included: “Complete Food Companion POINTS”, “Dining Out 
Companion POINTS”, “Fast Fixes”, and the Weight Watchers 3 Month Journal.  
Subjects also had access to web-based Momentum Program information with the 
monthly pass subscription. All subjects attended meetings at the Weight Watchers site 
located in Bryan, Texas.    
Medical Monitoring 
 Interested participants filled out medical histories at the familiarization session.  
Based on review of this information, the study coordinator determined whether the 
participant had met entry criteria in order to participate in the study. Participants with 
uncontrolled metabolic disorders, known electrolyte abnormalities, heart disease, 
arrhythmias, diabetes, or thyroid disease; a history of hypertension, hepatorenal, 
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musculoskeletal, autoimmune, or neurological disease were not allowed to participate in 
the study. Participants with a controlled medical condition had their physicians complete 
and sign the physician’s consent form prior to participation in the study. 
 In preparation for a medical emergency, the ESNL laboratory was equipped with 
an automated electronic defibrillator.  All ESNL personnel were certified in CPR and 
first aid and were trained on emergency procedures.  No less than two researchers 
worked with each participant during testing sessions.  In the event of any emergency, 
one researcher would have checked for vital signs and began any necessary interventions 
while the other researcher would have contacted the Texas A&M emergency services at 
extension 9-911.  Participants were instructed to report any unexpected problems or 
adverse events they encountered during the course of the study to the study coordinator 
Michelle Mardock, MS, RD.  If clinically significant side effects were reported, the 
participant would have been referred to their personal physician. No adverse events were 
reported during the course of the study. 
Testing Sessions 
 Participants were instructed to refrain from exercise for 48 hours and fast for at 
least 12 hours prior to reporting to the ESNL for testing sessions. Baseline testing 
sessions and 16 week testing sessions were identical and consisted of dietary inventory 
review, weekly physical activity assessment [International Physical Activity 
Questionnaire (IPAQ)], anthropometric assessments (body mass, waist and hip 
circumference); resting energy expenditure, resting heart rate and blood pressure, body 
composition analysis (DEXA); blood collection (metabolic panels, blood lipids, white 
 38 
 
and red blood cells); cardiorespiratory and muscular endurance and fitness assessments; 
psychosocial assessments [standardized quality of life (SF-36) and eating satisfaction 
inventories].  Additional testing sessions occurred during the fourth, tenth, and twelfth 
weeks and consisted of all baseline measures excluding cardiorespiratory and muscular 
fitness assessments.    
Methods and Procedures 
Dietary Inventories 
 A registered dietitian instructed all subjects on precise documentation of food 
intake and accurate estimation of food portion size. Participants recorded all food and 
fluids consumed over a four day period (including one weekend day) prior to each 
testing session. Dietary inventories were reviewed with participants at each testing 
session to ensure accuracy, completeness, and legibility. Dietary information was then 
analyzed to determine the average caloric intake and macronutrient intake using Food 
Processor Nutrition Analysis Software Version 9.1.0 (ESHA Nutrition Research, Salem, 
OR).  A registered dietitian reviewed all analyzed dietary information.   
Weekly Physical Activity Assessment 
 Physical activity patterns were quantified by assessing responses to the 7 day 
version of the International Physical Activity Questionnaire (IPAQ) 175-177. This 
assessment tool evaluated the frequency and intensity of job-related physical activity; 
transportation physical activity; housework, house maintenance, and caring for family 
related physical activity; and recreation, sports, and leisure-time physical activity based 
on established metabolic equivalent (MET) levels for common activities.  The IPAQ 
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defined light physical activity as walking level intensities (3.3 METs), moderate physical 
activity as activities at a 4.0 MET level, and vigorous physical activity as activities at an 
8.0 MET level.  The IPAQ has been identified as a valid indicator of general changes in 
physical activity patterns 175-178.  
Anthropometric Measurements 
 Height was measured using standard anthropometry. Total body weight was 
measured using a Healthometer (Bridgeview, IL, USA) self-calibrating digital scale with 
a precision of +/-0.02 kg. Hip and waist measures were performed using a Gulick II tape 
measure per guidelines established by the American College of Sports Medicine 179.  
Resting Energy Expenditure Assessment  
 Resting energy expenditure assessments were conducted according to standard 
protocols using the Parvo Medics TrueMax 2400 Metabolic Measurement System 
(ParvoMedics, Inc, Sandy, UT, USA). This test was conducted in a fasted state with the 
participants lying supine on an exam table. A clear metabolic canopy was placed over 
the subject’s head and neck, so that resting oxygen uptake and energy expenditure could 
be determined. The participants remained motionless without falling asleep for 
approximately 20 minutes.  Metabolic measurements were recorded after the first 10 
minutes during a five minute period in which principle variables, such as oxygen uptake, 
changed less than 5% 180. Mean test-retest reliability studies on 14 participants from a 
previous study revealed test-retest correlations (r) of collected oxygen uptake range from 
0.315 to 0.901 (mean 0.638) and a coefficient of variation range from 8.2% to 12.0% 
(mean 9.9%) with a mean intraclass coefficient of 0.942; p<0.001 35. 
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Resting Heart Rate and Blood Pressure 
 Heart rate was determined by palpitation of the radial artery using standard 
procedures 181. Blood pressure was assessed in the supine position after resting for 5 
minutes using a mercurial sphygmomanometer (American Diagnostic Corporation, 
model #AD-720, Hauppuage, NY, USA) using standard procedures 182.  
Body Composition 
 Participants had bone density and body composition (excluding cranium) 
determined using a Hologic Discovery W QDR series Dual Energy X-ray 
Absorptiometry (DEXA) system (Hologic Inc, Waltham, MA, USA) equipped with 
APEX software (APEX Corporation Software, Pittsburgh, PA, USA).  Dual-energy X-
ray absorptiometry has been validated as an accurate method for body composition 
assessment 183-186.  Mean test-retest reliability studies performed on male athletes with 
this Hologic system have yielded mean coefficients of variation for total bone mineral 
content and total fat free/soft tissue mass of 0.31% to 0.45% with a mean intra-class 
correlation of 0.985 187.  Participants were informed of any inherent risks that could 
present from radiation exposure and completed a radiation exposure questionnaire prior 
to all scans.  Quality control (QC) calibration procedures were performed on a spine 
phantom (Discovery W-CALIBER Model DPA/QDR-1 anthropometric spine phantom) 
prior to each testing session. During DEXA testing, participants lay down on their back 
in a standardized position.  A low dose of radiation scanned their entire body for 
approximately six minutes.  
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 The DEXA segments regions of the body (right arm, left arm, trunk, right leg, 
and left leg) into three compartments for determination of fat, soft tissue (muscle), and 
bone mass. Radiation exposure from DEXA for the whole body scan is approximately 
1.5 mR per scan. This is similar to the amount of natural background radiation a person 
would receive in one month while living in College Station, Texas. The maximal 
permissible x-ray dose for non-occupational exposure is 500 mR per year. Total 
radiation dose was estimated to be less than 9 mR for the entire study.  
Blood Collection and Analysis Procedures 
 Fasted and whole blood and serum samples were collected using standard 
phlebotomy techniques. Whole blood samples were analyzed for complete blood counts 
with platelet differentials utilizing an Abbott Cell Dyn 3500 automated hematology 
analyzer (Abbott Laboratories, Abbott Park, IL, USA).  Serum samples were analyzed 
for a complete metabolic panel by Quest Diagnostics (Quest Diagnostics, 5850 
Rogerdale Road, Houston TX, USA 77072) using an Olympus AAU 5400 Chemistry 
Immuno Analyzer (Olympus America Inc., Center Valley, PA, USA).  Serum leptin was 
determined in duplicate using a commercially available enzyme linked 
immunoabsorbent assay (ELISA) kit (No. 11-LEPHU-E01, ALPCO, Salem, NH, USA) 
using a BioTek ELX-808 Ultramicroplate reader (BioTek Instruments Inc, Winooski, 
VT, USA) at an optical density of 450 nm against a known standard curve utilizing 
standard procedures using BioTek Gen5 Analysis software (BioTek Instruments Inc, 
Winooski, VT, USA). Intra-assay coefficient of variation has been shown to range from 
3.7% to 5.5%, whereas the inter-assay coefficient of variation of has a ranged from 5.8% 
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to 6.8% (ALPCO, Salem, NH, USA).  Fasting insulin was also assayed in duplicate via a 
commercially available Enzyme Linked Immunosorbent assay (ELISA) kit (No. 80-
INSHU-E10, ALPCO, Salem, NH, USA) using a BioTek ELX-808 Ultramicroplate 
reader (BioTek Instruments Inc, Winooski, VT, USA) at an optical density of 450 nm 
against a known standard curve using standard procedures with BioTek Gen5 Analysis 
software (BioTek Instruments Inc, Winooski, VT, USA). The intra-assay coefficient of 
variation has been shown to ranged from 2.9% to 6.2%, with an inter-assay coefficient of 
variation range of 5.4% to 8.6% (ALPCO, Salem, NH, USA). The homeostasis Model 
Assessment for insulin resistance (HOMA-IR) was calculated as the product of fasting 
insulin times fasting glucose expressed in standard units divided by 405 188.  
Maximal Cardiopulmonary Exercise Test  
 Cardiopulmonary exercise tests were performed at baseline and 16 weeks by 
ESNL exercise physiology graduate students in accordance to standard procedures 
described by the American College of Sports Medicine’s (ACSM) Guidelines for 
Exercise Testing and Prescription 179.  The Nasiff Cardio Card electrocardiograph 
(Nasiff Associates, Inc, Central Square, NY, USA) was used to assess heart function 
using a standard 12-lead arrangement 179. Electrode sites were cleansed with a sterile 
alcohol wipe using a circular motion. Once the site was dry, electrodes were placed on 
the right subclavicular fossa (RA), the left subclavicular fossa (LA), the 4th intercostals 
space at the right sternal border (V1), the 4th intercostal space at the left sternal border 
(V2), equidistant between V2 and V4 (V3), the 5th intercostal space at the mid-
clavicular line (V4), the 5th intercostal space at the anterior axillary line (V5), the 5th 
 43 
 
intercostals space at the midaxillary line (V6), and the right abdomen (RL) and left 
abdomen (LL) line.  While the subject was in a supine position, resting blood pressure, 
heart rate, and a 12-lead ECG were obtained. The 12-lead ECG was reviewed to ensure 
that no contraindications for exercise testing were present based on the ACSM 
guidelines 181. The participant was then asked to stand and step onto the treadmill. A 
standing blood pressure, heart rate, and a 12-lead ECG was obtained and reviewed.  A 
sterile mouthpiece, attached to a head harness, was then secured on the participant and a 
nose clip placed on their nose. Expired gases were collected using a ParvoMedics 2400 
TrueMax Metabolic Measurement System (ParvoMedics Inc, Sandy, UT, USA). Once 
the participant was ready to begin the test protocol, the participant was asked to straddle 
the treadmill with both legs while the treadmill was turned on to a speed of 2.0 mph and 
at a 0% grade. The participant then carefully stepped onto the belt while still gripping 
the handrails with both hands. Once comfortable walking on the treadmill, they let go of 
the handrail and began walking freely. The participant performed the Bruce treadmill 
protocol 189 following the speeds and grades delineated in Table 3.  The mean coefficient 
of variation for assessing peak Vo2 utilizing the Bruce protocol has been shown to be 
6.5% (range, 2.0-14%) 190.  Heart rate (HR), ECG tracings, and expired gases were 
monitored continuously throughout the exercise test. Blood pressure (BP) and ratings of 
perceived exertion (RPE) were obtained toward the end of each stage. The participant 
was encouraged to exercise to their maximum unless they experienced clinical signs that 
required test termination as stated by the ACSM’s Guidelines for Exercise Testing and 
Prescription 181.  These signs included: a decline in systolic blood pressure > 10 mmHg 
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from baseline, angina, ataxia, dizziness, syncopy, cyanosis, nausea, dangerous 
dysrhythmias (ventricular tachycardia, supraventricular tachycardia, new atrial 
fibrillation, or A-V block, increasing or multi-form premature ventricular contractions), 
an excessive rise in systolic blood pressure over 250 mmHg or diastolic over 115 
mmHg, chronotropic impairment, technical difficulties of the monitoring system, or 
other signs or symptoms necessitating termination of the test. Once the exercise test was 
complete, the participant continued an active recovery period for three minutes followed 
by a three minute seated recovery period.   
 
Table 3. Bruce Protocol 
Stage Speed (MPH) Grade (%) Duration (minutes) METS 
Warm-up 2.0 0 2 3.3 
1 1.7 10 3 4.5 
2 2.5 12 3 6.5 
3 3.4 14 3 9.7 
4 4.2 16 3 13.5 
5 5.0 18 3 17 
6 5.5 20 3 20.5 
 
 
Isotonic Strength Tests 
 
 Participants had their 1RM determined using an isotonic Olympic bench press 
(Nebula Fitness, Versailles, OH, USA) and a standard hip sled/leg press (Nebula Fitness, 
Versailles, OH, USA) to determine changes in maximal strength according to 
standardized procedures. Hand positioning on the bench press and foot and seat position 
on the hip sled/leg press were standardized between trails. Muscular endurance was 
assessed by having participants perform as many repetitions as possible at 80% of their 
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predetermined 1RM on the bench press and leg press using standard lifting techniques 
and testing criteria 191. Test-retest reliability of performing these strength tests on 
resistance-trained subjects in the ESNL have yielded low mean coefficients of variation 
and high reliability for the bench press (1.9%, intraclass r = 0.94) and leg press/hip sled 
(0.7%, intraclass r = 0.91) 192. 
 All strength/exercise tests were conducted using standard procedures and were 
supervised by certified lab assistants experienced in conducting strength/anaerobic 
exercise testing. In order to test for upper body strength and endurance, participants 
performed a one repetition maximum (1 RM) test on the isotonic bench press and the 
Nebula Fitness (Versailles, OH, USA) Olympic Power Station (#1005). Participants 
performed a warm-up (2 sets of 10 repetitions at approximately 50% of anticipated 
1RM) followed by progressive lifts starting at about 70% of anticipated 1RM and 
increasing by 5 – 10 lbs until 1 RM was reached.  Once the 1RM was attained, subjects 
performed as many repetitions as possible with 80% of their 1 RM effort.  Participants 
rested for 10 minutes, then performed a warm up of 8-10 repetitions at approximately 
50% of anticipated maximum on the Nebula 45° Leg press. Participants performed 
successive lifts on the leg press starting at about 70% of anticipated 1RM and increasing 
by 10 – 25 lbs until 1RM was attained. Once the 1RM was achieved, subjects performed 
as many repetitions as possible with 80% of their 1 RM effort.   
Psychometric Assessments  
 Participants completed the SF-36 Health-Related Quality of life (QOL) inventory 
140 and an appetite/eating satisfaction questionnaire. The SF-36 quality of life 
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questionnaire has been validated for the measurement of psychosocial dimensions that 
may be influenced by general improvement in health and/or weight loss 145, 193. The SF 
36 questionnaire assessed a number of physical and mental components including 
physical functioning (ie, the ability to perform most vigorous physical activities without 
limitation to health), role physical (ie, ability to work and perform daily activities), 
bodily pain (ie, limitations due to pain), general health (ie, assessment of personal 
health), vitality (ie, feeling of having energy), social functioning (ie, ability to perform 
normal social activities), role emotion (ie, problems with work or other daily activities), 
and mental health (state of feelings of peacefulness, happiness, and calm). Eating 
Satisfaction Questionnaires were performed for comparison to previous curves 
intervention studies. These questionnaires satisfied the requirements of the sponsor of 
this study and are listed as a limitation of the study as they have not been validated or 
tested for reliability.  Following the final testing session, participants were asked to 
complete a post-study questionnaire to assess their impressions about the weight loss 
study.  
Statistical Methods 
 Only subjects who completed the 16 week trial with greater than 80% 
compliance were included in the analyses. Missing data, if any, were replaced using the 
last observed value method or by replacing missing values with the group mean method.  
Baseline demographic data were analyzed by one-way Analysis of Variance (ANOVA).   
Data were normally distributed.  Study data were analyzed by Multivariate Analysis of 
Variance (MANOVA) with repeated measures (PASW Statistics version 19, 2011, SPSS 
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Inc, Chicago, IL.).  Overall MANOVA effects were examined using Wilks’ Lamda time 
and group x time p-levels as well as MANOVA univariate ANOVA group effects. 
Greenhouse-Geisser univariate tests of within-subjects time and group x time effects and 
between-subjects univariate group effects were reported for each variable analyzed 
within the MANOVA model. In some instances, repeated measures ANOVA was run on 
variables not included in a MANOVA design with univariate group, time, and group x 
time interaction effects reported.  Variables with baseline differences determined by 
ANOVA were analyzed using analysis of covariance (ANCOVA).  Delta values or 
percent difference were calculated and analyzed on select variables by ANOVA for 
repeated measures to assess changes from baseline values.  Delta values were calculated 
by subtracting the first testing session (T1) from later testing sessions (T6-T1). Percent 
differences were calculated by subtracting T1 from the later testing session, then 
performing division by T1 followed by multiplication by 100 [(T6-T1)/T1·100]. Data 
were considered statistically significant when the probability of type I error was 0.05 or 
less and statistical trends were considered when the probability error ranged between 
>0.05 to p<0.10.  If a significant group, treatment and/or interaction alpha level was 
observed, Tukey’s least significant difference (LSD) post hoc analyses were performed 
to determine where significance was obtained. Power analysis of previous studies using 
similar designs and subject populations indicated that a sample size of 30 subjects per 
group yielded high power (>0.8) for delta values of 0.75 to 1.25 for weight and fat loss. 
All data are presented as means ± standard deviation. 
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CHAPTER IV 
RESULTS 
 
Methods 
Experimental Approach 
This study was conducted as a randomized comparative effectiveness trial from June 
2009 to June 2011.  Participants were matched based on age and body mass index (BMI: 
calculated as kg/m2) and randomized into one of two weight reduction interventions. 
Dietary intake and weekly physical activity, anthropometric measurements, resting 
energy expenditure (REE), resting heart rate (RHR) and systolic and diastolic blood 
pressure (BP), body composition, serum clinical chemistry panels, whole blood counts 
and hormone concentrations, and quality of life were assessed at 0, 4, 10, and 16 weeks 
to determine differences in weight reduction program effects. Maximal cardiopulmonary 
exercise capacity (Peak VO2) and upper and lower body isotonic strength and endurance 
were assessed at 0 and 16 weeks to ascertain chronic program effects.   
Participants 
This research protocol was reviewed and approved by the university Institutional Review 
Board before initiation. Participants were recruited through advertisements in local 
newspapers, campus flyers, radio and Internet advertisements. Interested participants 
were asked to contact the laboratory for an initial telephone prescreening interview. 
General entrance criteria included being an apparently healthy woman between ages of 
18 and 50 years with a BMI greater than 25 and no recent participation in a diet or 
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exercise program.  Individuals who met initial entrance criteria were invited to attend a 
familiarization session in which the details of the study were explained, human subject 
consent forms were signed and personal and medical history information was obtained.  
Participants were not allowed to participate in the study if the subjects reported the 
following at baseline: a recent weight change of (±3.2 kg or 7 lb) within 3 months; any 
uncontrolled metabolic or cardiovascular disorder, including known electrolyte 
abnormalities, heart disease, arrhythmias, diabetes, or thyroid disease, or a history of 
hypertension, hepatorenal, musculoskeletal, autoimmune, or neurological disease; taking 
any weight loss supplements and/or ergogenic levels of nutritional supplements that 
affect muscle mass, anaerobic exercise capacity, anabolic/catabolic hormone levels, or 
weight loss within 3 months; a history of pregnancy or lactation within the past 12 
months or intentions to become pregnant during the next 12 months; participation in a 
regular exercise program within the past 3 months; and, any condition that is classified 
as high risk for cardiovascular disease according to American College of Sports 
Medicine criteria 194.  Information obtained during the familiarization session was 
reviewed by the research coordinator to determine eligibility to participate in the study.  
Those meeting eligibility criteria were scheduled to undergo baseline assessments. 
Participants with a controlled medical condition had their physicians complete and sign 
the physician’s consent form prior to participation in the baseline assessment.   
 A total of 149 women responded to advertisements to participate in this study. Of 
these, 127 met phone interview entrance criteria and were invited to attend 
familiarizations sessions. One hundred and twenty women showed up for familiarization 
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sessions and met entrance criteria to participate in the study after evaluation of medical 
history and obtaining consent. Of these women, 98 women completed baseline testing 
and were cleared to participate in the study. Fifty one women completed the 16 week 
study. The primary reasons participants dropped out of the study were due to time 
constraints, job conflicts, transportation difficulties, and relocation.   
 
 
 
 
 
 
 
 
 
 
 
 
Testing Sessions 
Participants were instructed to refrain from exercise for 48 hours and fast for at least 12 
hours prior to reporting to the ESNL for testing sessions. Baseline testing sessions and 
16 week testing sessions were identical and consisted of dietary inventory review; 
weekly physical activity assessment [International Physical Activity Questionnaire 
Withdrawal After 
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difficulties, and 
relocation. 
 
Figure 1.  Consort diagram for participation.   
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(IPAQ)]; anthropometric assessments (body mass, waist and hip circumference); resting 
energy expenditure; resting heart rate and systolic and diastolic blood pressure (BP); 
body composition analysis (DEXA); blood collection (metabolic panels, blood lipids, 
white and red blood cells); cardiorespiratory and muscular fitness assessments; 
psychosocial assessments [standardized quality of life (SF-36) and eating satisfaction 
inventory]. Additional testing sessions occurred during the fourth and tenth weeks and 
consisted of all baseline measures excluding cardiorespiratory and muscular fitness 
assessments.    
Program Intervention 
Participants were randomized into one of two popular weight loss program intervention 
groups.   Participants in the Curves group (C) followed the Curves Fitness and Weight 
Management Plan (C program).  In concurrence with this plan, subjects followed the 
phase 1 higher protein weight loss diet (1,200 kcals/day) for one week and the phase 2 
higher protein weight loss diet (1,500 kcals/day) for 3 weeks. The macronutrient content 
for both phase 1 and 2 diets was (45% protein, 30% carbohydrate, 25% fat). Phase 3 
consisted of a metabolic recovery phase, where subjects followed a 2,000-2,500 kcals/d 
diet with a macronutrient breakdown of (30% protein, 45% carbohydrate, 25% fat) for 
two weeks.  Subjects experiencing a weight increase of 3 pounds during phase 3 were 
instructed to return to Phase 1 for 2-3 days until their weight returned back down. The 
three dietary phases were cycled over the course of 16 weeks. A registered dietitian 
reviewed the higher protein diet and exercise plan with subjects. Participants were 
encouraged to consume 2 multivitamins, 800 mg of calcium, and 520 mg of Omega-3 
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fatty acids daily. The dietitian also met with subjects weekly throughout the study to 
discuss any dietary challenges or concerns.   
 The physical training protocol included one regular curves circuit work out and 
two circuit combined with Zumba workouts each week for 16 weeks, while maintaining 
a greater than 80% compliance record (38 out of 48 workouts).  The circuit utilized the 
computerized CurvesSmart system (curves International, Waco, TX, USA) equipped 
with software designed by MYTRAK (version 4.2.0.0, copyright 2004-2010, MYTRAK 
Health System, Mississauga, Ontario, Canada).  The circuit consisted of 13 bi-directional 
hydraulic resistance exercise machines that worked all major muscle groups (ie, elbow 
flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, 
chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, 
chest flies, oblique, shoulder shrug/dip, hip extension, and side bends).  During the 
circuit workouts, subjects were instructed to complete as many repetitions as possible 
during a 30 second time period on each resistance machine. Between machines, subjects 
performed floor-based aerobic exercises or stepping exercise designed to maintain an 
elevated heart rate. Subjects performed the entire circuit twice during the 26 minute 
regular circuit workout.  During the circuit combined with Zumba workout, subjects 
performed 1 minute of Zumba dance moves in between 1 minute of resistance exercise 
on each machine.  All Zumba classes were taught by a certified Zumba instructor.  All 
circuit workouts were supervised by trained fitness instructors who assisted subjects with 
proper exercise technique and self-monitoring of heart rate in order to maintain an 
exercise heart rate between 60-80% of target heart rate using age-predicted maximal 
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heart rate (220-age). Subjects also performed 5 minutes of whole body stretching 
following circuit workouts.  In addition to circuit training, subjects were encouraged to 
walk for 30 minutes at a brisk pace [60-80% of heart rate reserve (maximum HR- 
minimum HR)] on most days of the week.  The circuit equipment was located in the 
Exercise and Sports Nutrition Laboratory at Texas A&M University.   
 Participants assigned to the Weight Watchers Group (W) took part in the Weight 
Watchers Momentum Program (W program) and were signed up for the monthly pass 
subscription.  Subjects were required to attend 1 meeting each week with an 80% 
compliance record (13 out of 16 meetings).  Subjects emailed the study coordinator each 
time they attend a meeting. Meetings consisted of group discussions and some individual 
interaction as members weighed in. The core program material was delivered over ten 
weeks and included: food plans based on a system of points, exercise recommendations, 
strategies for dealing with hunger, successful habits, strategies for eating out, tracking 
intake and activity, eating with others, recipes, workout variation, and plateaus. The 
program also encouraged subjects to perform 30 minutes of activity on most days of the 
week.  All subjects attended meetings at the Bryan Texas site.     
Methods and Procedures 
Dietary Inventories 
A registered dietitian instructed all subjects on precise documentation of food intake and 
accurate estimation of food portion size.  Participants recorded all food and fluids 
consumed over a four day period (including one weekend day) prior to each testing 
session. Dietary inventories were reviewed with participants at each testing session to 
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ensure accuracy, completeness, and legibility. Dietary information was then analyzed to 
determine the average caloric intake and macronutrient content using Food Processor 
Nutrition Analysis Software Version 9.1.0 (ESHA Nutrition Research, Salem, OR, 
USA).  A registered dietitian review all analyzed dietary information.  
Weekly Physical Activity Assessment 
Physical activity patterns were quantified by assessing responses to the 7 day version of 
the International Physical Activity Questionnaire (IPAQ) 175-177. This assessment tool 
evaluated the frequency and intensity of job-related physical activity; transportation 
physical activity; housework, house maintenance, and caring for family related physical 
activity; and recreation, sports, and leisure-time physical activity based on established 
metabolic equivalent (MET) levels for common activities.  The IPAQ defined light 
physical activity as walking level intensities (3.3 METs), moderate physical activity as 
activities at a 4.0 MET level, and vigorous physical activity as activities at an 8.0 MET 
level.  The IPAQ has been identified as a valid indicator of general changes in physical 
activity patterns 175-178.  
Anthropometrics and Body Composition 
Height and total body weight were determined according to standard procedures using a 
Healthometer (Bridgeview, IL, USA) self-calibrating digital scale with a precision of +/-
0.02 kg. Hip and waist circumference were measured using a Gulick tension 
standardized measuring tape per guidelines established by the American College of 
Sports Medicine 181. Bone density and body composition (excluding cranium) was 
assessed using a Hologic Discovery W QDR series Dual Energy X-ray Absorptiometry 
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(DEXA) system (Hologic Inc, Waltham, MA, USA) equipped with APEX software 
(APEX Corporation Software, Pittsburgh, PA, USA). Mean coefficients of variation for 
bone mineral content and bone mineral density measurements performed on the spine 
phantom ranged between 0.41% and 0.55%. Mean test-retest reliability studies 
performed on male athletes with this Hologic system have yielded mean coefficients of 
variation for total bone mineral content and total fat free/soft tissue mass of 0.31% to 
0.45% with a mean intra-class correlation of 0.985 187.   
Resting Energy Expenditure  
Resting energy expenditure assessments were conducted according to standard protocols 
using the Parvo Medics TrueMax 2400 Metabolic Measurement System (ParvoMedics, 
Inc, Sandy, UT, USA). This test was conducted in a fasted state with the participants 
lying supine on an exam table. A clear metabolic canopy was placed over the subject’s 
head and neck, so that resting oxygen uptake and energy expenditure could be 
determined. The participants remained motionless without falling asleep for 
approximately 20 minutes.  Metabolic measurements were recorded after the first 10 
minutes during a five minute period in which principle variables, such as oxygen uptake, 
changed less than 5% 180. Mean test-retest reliability studies on 14 participants from a 
previous study revealed test-retest correlations (r) of collected oxygen uptake range from 
0.315 to 0.901 (mean 0.638) and coefficient of variation range from 8.2% to 12.0% 
(mean 9.9%) with a mean intraclass coefficient of 0.942; p<0.001 35. 
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Blood Collection and Analysis Procedures 
Fasted and whole blood and serum samples were collected using standard phlebotomy 
techniques. Whole blood samples were analyzed for complete blood counts with platelet 
differentials utilizing an Abbott Cell Dyn 3500 automated hematology analyzer (Abbott 
Laboratories, Abbott Park, IL, USA).  Serum samples were analyzed for a complete 
metabolic panel by Quest Diagnostics (Quest Diagnostics, 5850 Rogerdale Road, 
Houston TX, USA 77072) using an Olympus AAU 5400 Chemistry Immuno Analyzer 
(Olympus America Inc., Center Valley, PA, USA).  Serum leptin was determined in 
duplicate using a commercially available enzyme linked immunoabsorbent assay 
(ELISA) kit (No. 11-LEPHU-E01, ALPCO, Salem, NH) using a BioTek ELX-808 
Ultramicroplate reader (BioTek Instruments Inc, Winooski, VT) at an optical density of 
450 nm against a known standard curve utilizing standard procedures using BioTek 
Gen5 Analysis software (BioTek Instruments Inc, Winooski, VT). Intra-assay coefficient 
of variation has been shown to range from 3.7% to 5.5, whereas the inter-assay 
coefficient of variation of has a ranged from 5.8% to 6.8% (ALPCO, Salem, NH).  
Fasting insulin was also assayed in duplicate via a commercially available Enzyme 
Linked Immunosorbent assay (ELISA) kit (No. 80-INSHU-E10, ALPCO, Salem, NH) 
using a BioTek ELX-808 Ultramicroplate reader (BioTek Instruments Inc, Winooski, 
Vermont) at an optical density of 450 nm against a known standard curve using standard 
procedures with BioTek Gen5 Analysis software (BioTek Instruments Inc, Winooski, 
VT). The intra-assay coefficient of variation has been shown to ranged from 2.9% to 
6.2%, with an inter-assay coefficient of variation range of 5.4% to 8.6% (ALPCO, 
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Salem, NH). The homeostasis Model Assessment for insulin resistance (HOMA-IR) was 
calculated as the product of fasting insulin times fasting glucose expressed in standard 
units divided by 405 188.  
Exercise Capacity 
Resting heart rate was determined by palpitation of the radial artery and resting blood 
pressure was assessed in the supine position utilizing a mercurial sphygmomanometer 
(American Diagnostic Corporation, model #AD-720, Hauppuage, NY, USA) using 
standard procedures 181.  Maximal Cardiopulmonary exercise tests (peak VO2) were 
performed utilizing the Bruce treadmill protocol 189. Standard test termination criteria 
were utilized to assess maximal volitional fatigue 181. The Nasiff Cardio Card 
electrocardiograph (Nasiff Associates, Inc, Central Square, NY, USA) was used to 
assess heart function using a standard 12-lead arrangement 181. Expired gases were 
collected using a ParvoMedics 2400 TrueMax Metabolic Measurement System 
(ParvoMedics Inc, Sandy, UT, USA).  Gas and flow sensors were calibrated before 
testing and were found to be within 3% of previous calibration points.  
 Participants had their 1RM determined using an isotonic Olympic bench press 
(Nebula Fitness, Versailles, OH, USA) and a standard hip sled/leg press (Nebula Fitness, 
Versailles, OH, USA) to determine changes in maximal strength. Hand positioning on 
the bench press and foot and seat position on the hip sled/leg press were standardized 
between trails. Muscular endurance was assessed by having participants performed as 
many repetitions as possible at 80% of their predetermined 1RM on the bench press and 
leg press using standard lifting techniques and testing criteria 191.  Test-retest reliability 
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of performing these strength tests on resistance-trained subjects in the ESNL have 
yielded low mean coefficients of variation and high reliability for the bench press (1.9%, 
intraclass r = 0.94) and leg press/hip sled (0.7%, intraclass r = 0.91) 192.  
Psychometric Assessments  
Participants completed the SF-36 Health-Related Quality of life (QOL) inventory 140 and 
an appetite/eating satisfaction questionnaire. The SF-36 quality of life questionnaire has 
been validated for the measurement of psychosocial dimensions that may be influenced 
by general improvement in health and/or weight loss 145, 193. The SF 36 questionnaire 
assessed a number of physical and mental components including physical functioning 
(ie, the ability to perform most vigorous physical activities without limitation to health), 
role physical (ie, ability to work and perform daily activities), bodily pain (ie, limitations 
due to pain), general health (ie, assessment of personal health), vitality (ie, feeling of 
having energy), social functioning (ie, ability to perform normal social activities), role 
emotion (ie, problems with work or other daily activities), and mental health (state of 
feelings of peacefulness, happiness, and calm). Eating Satisfaction Questionnaires were 
performed for comparison to previous curves intervention studies. These questionnaires 
satisfied the requirements of the sponsor of this study and are listed as a limitation of the 
study as they have not been validated or tested for reliability.  Following the final testing 
session, participants were asked to complete a post-study questionnaire to assess their 
impressions about the weight loss study.  
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Statistical Methods 
Only subjects who completed the 16 week trial were included in the analyses. Missing 
data, if any, were replaced using the last observed value method or by replacing missing 
values with the group mean method.  Baseline demographic data were analyzed by one-
way Analysis of Variance (ANOVA).   Data were normally distributed.  Study data were 
analyzed by Multivariate Analysis of Variance (MANOVA) with repeated measures 
(PASW Statistics version 19, 2011, SPSS Inc, Chicago, IL.).  Overall MANOVA effects 
were examined using Wilks’ Lamda time and group x time p-levels as well as 
MANOVA univariate ANOVA group effects. Greenhouse-Geisser univariate tests of 
within of within-subjects time and group x time effects and between-subjects univariate 
group effects were reported for each variable analyzed within the MANOVA model. In 
some instances, repeated measures ANOVA was run on variables not included in a 
MANOVA design with univariate group, time, and group x time interaction effects 
reported.  Variables with baseline differences determined by ANOVA were analyzed 
using analysis of covariance (ANCOVA).  Delta values or percent difference were 
calculated and analyzed on select variables by ANOVA for repeated measures to assess 
changes from baseline values.  Delta values were calculated by subtracting the first 
testing session (T1) from later testing sessions (T6-T1). Percent differences were 
calculated by subtracting T1 from the later testing session, then performing division by 
T1 followed by multiplication by 100 [(T6-T1)/T1·100]. Data were considered 
statistically significant when the probability of type I error was 0.05 or less and 
statistical trends were considered when the probability error ranged between >0.05 to 
 60 
 
p<0.10.  If a significant group, treatment and/or interaction alpha level was observed, 
Tukey’s least significant difference (LSD) post hoc analyses were performed to 
determine where significance was obtained. Power analysis of previous studies using 
similar designs and subject populations indicated that a sample size of 30 subjects per 
group yielded high power (>0.8) for delta values of 0.75 to 1.25 for weight and fat loss. 
All data are presented as means ± standard deviation. 
Results  
Fifty-one apparently healthy but sedentary and obese women (age 35±8 yrs, height 
163±7 cm; weight 90±1 kg; BMI 34±5 kg/m2; 47±7 % body fat) completed the 16-week 
study (n=24 C group; n=27 W group) with greater than 80% compliance.  No significant 
differences were observed between groups in baseline age, height, weight, BMI, or 
percent body fat as determined by ANOVA (Table 4).   
 
 
 
 
 
 
 
 
 
 
 
 
Dietary Intake 
Table 5 presents changes in nutritional intake at 0, 4, 10, and 16 weeks of program 
intervention. Complete food records were obtained on all participants completing the 
Table 4.  Baseline demographics for the Curves (C) and Weight Watchers 
(W) groups  
                                           Group            C group         W group     
                                           (n-51)             (n=24)           (n=27)         p-value 
Age (years) 34.5±7.7 35.1±9.2 34.0±6.2 0.63 
Height (cm) 162.8±7.0 163.0±7.4 162.6±6.7 0.84 
Weight (kg) 90.1±14.5 90.8±15.7 89.5±13.6 0.77 
BMIa (kg/m²) 34.0±5.1 34.1±5.1 33.9±5.2 0.90 
DEXAb fat mass (%) 46.5±7.1 48.1±6.5 45.1±7.3 0.14 
 
All data is presented as means ± SD at baseline. Significance level was set at 0.05. 
aBody mass Index 
 aDual Energy X-ray Absorptiometry 
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study.  MANOVA analyses were run on energy intake (kcals/kg/d), macronutrient intake 
expressed in g/kg/day, and macronutrient intake expressed as a percentage of total 
calories consumed. MANOVA analysis of dietary intake data revealed an overall time  
 
Table 5.  Changes in nutritional intake obtained at 0, 4, 10 and 16 weeks of program participation 
for the Curves (C) and Weight Watchers (W) groupsa   
                                             Week  
Variable Group 0 4 
 
10 
 
16 p-value 
                                Mean±Standard Deviation  
 
Energy Intake  
(kcals/kg/d) 
C 
W 
Total 
19.17±5.99 
22.32±6.80 
20.84±6.55 
16.53±4.23b 
15.58±4.52b 
16.03±4.37b 
15.83±4.04b 
16.27±4.12b 
16.06±4.05b 
17.24±4.54b 
15.67±4.22b 
16.50±4.42b 
Gc = 0.34 
Td = 0.001 
Ie = 0.04 
CHO Intakef 
(g/kg/d) 
C 
W 
Total 
1.94±0.89 
2.26±0.88 
2.11±0.89 
1.58±0.66b 
1.70±0.53b 
1.64±0.59b 
1.54±0.62b 
1.69±0.55b 
1.62±0.58b 
1.51±0.68b 
1.89±0.50b 
1.71±0.61b 
G = 0.12 
T = 0.001 
I = 0.43 
Protein Intake  
(g/kg/d) 
C 
W 
Total 
0.89±0.27 
0.86±0.23 
0.88±0.25 
1.07±0.28gb 
0.79±0.24 
0.93±0.29b 
0.94±0.31 
0.85±0.25 
0.89±0.28 
1.00±0.35g 
0.80±0.22 
0.90±0.30 
G = 0.02 
T = 0.44 
I= 0.005 
Fat Intake  
(g/kg/d) 
C 
W 
Total 
0.74±0.27 
0.90±0.32 
0.82±0.31 
0.62±0.18gb 
0.47±0.20b 
0.54±0.20b 
0.58±0.19b 
0.48±0.19b 
0.53±0.20b 
0.59±0.25b 
0.58±0.18b 
0.58±0.22b 
G = 0.64 
T = 0.001 
I= 0.001 
CHO Intake  
(%) 
C 
W 
Mean 
42±9 
43±9 
42±9 
38±7b 
47±9 
43±10 
41±11 
46±9 
43±10 
40±10 
47±6 
43±9 
G = 0. 003 
T = 0.90 
I = 0.06 
Protein Intake  
(%) 
C 
W 
Mean 
21±5g 
17±3 
19±5 
27±6gb 
22±4 
24±6 
25±7 
23±5 
24±6 
27±7g 
20±3 
23±6 
G = 0.006 
T =0.75 
I= 0.02 
Fat Intake 
(%) 
C 
W 
Mean 
37±8 
39±8 
38±8 
35±6h 
30±8b 
32±8b 
34±7h 
30±9b 
32±8b 
33±6b 
32±6b 
33±6b 
G = 0.11      
T = 0.001 
I = 0.02 
aComplete food intake records were obtained at 0, 4, 10, and 16 weeks for 24 participants in the C group and 27 
participants in the W group (n=51).  Data were analyzed using ESHA Food Processor Nutritional Analysis Software 
(Version 8.6).    
bp<0.05 difference from baseline. 
cG=group alpha level. 
dT=time alpha level. 
eI=group x time interaction alpha level. 
fCarbohydrate intake 
gp<0.01 difference between C and W groups. 
hp<0.05 difference between C and W groups. 
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(Wilks’ Lamda p=0.001) and overall time by diet interaction (Wilks’ Lamda p=0.03) 
observed.  MANOVA univariate analysis revealed the W group had a greater reduction 
in energy intake per kilogram body weight than the C group (C -2.6±5.4, -3.3±5.1, -
3.5±6.0; W -6.7±5.8, -6.0±6.2, -5.1±6.2 g/kg/d) with time (p=0.001) and time by diet  
(p=0.04) effects observed.  There was a greater reduction in fat intake in the W group (C 
-0.12±15, -0.16±0.31, -0.17±0.26; W -0.42±0.28,-0.41±0.33, -0.31± 0.34 g/kg/d) with 
time (p=0.001), time by diet (p=0.001) effects observed.  Univariate ANOVA also 
revealed the W group had a greater reduction in the percentage of energy intake from fat 
(C -2.6±8.6, -3.0±8.9, -3.7±7.4; W -9.6±9.5, -9.4±11.2, -6.7±8.8 %) with effects seen for 
time (p=0.001) and time by diet (p=0.02).   
 Carbohydrate intake decreased over time in both groups (C -0.36±0.68, -
0.40±0.61, -0.43±0.73; W -0.56±0.94, -0.57±0.87, -0.37±0.88 g/kg/d) with no significant 
difference between groups (p=0.43).  However, the percentage of kcalories consumed as 
carbohydrate tended to increase with reduced energy intake in the W group (C -3.5±8.2, 
-1.0±10.2, -2.0±9.0; W 4.0±11.0, 2.7±12.1, 3.5±9.1 %) with a trend in time by diet 
(p=0.06) and diet (p=0.003) effects observed.  The C group increased dietary protein 
intake (C 0.18±0.20, 0.05±0.30, 0.11±0.35; W -0.07±0.18, -0.01±0.26, -0.06±0.20 
g/kg/d) with both time by diet (p=0.005) and diet (p=0.02) effects observed.  One way 
ANOVA revealed the C group consumed a higher percentage of kcalories as protein at 
baseline (p=0.005). Univariate ANCOVA revealed the C group experienced a greater 
increase in the percentage of kcalories consumed as protein (C 6.4±7.1, 4.1±6.4, 6.1±7.7; 
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W 5.0±5.4, 6.2±6.5, 3.1±4.4 %) with significant time by diet (p=0.02) and group effects 
(p=0.006) observed.  
Physical Activity 
   
Table 6.  Changes in physical activity patterns values observed at 0, 4, 10 and 16 weeks of program 
participation for the Curves (C) and Weight Watchers (W) groupsa   
                                                Week  
Variable Group 0 4 10 16 p-value 
                                 
                                mean±standard deviation 
 
 
 
Low PAb 
(MET-min/weekc) 
 
C 
W 
Mean 
 
1,097±1,301 
703±1,170 
889±1,237 
 
1,240±1,222 
890±1,258 
1,054±1,241 
 
1,146±1,637 
1,467±2,022d 
1,316±1,840d 
 
1,370±1,722 
1,428±1,868d 
1401±1,783d 
 
Ge = 0.80 
Tf = 0.09 
Ig= 0.27 
Moderate PA  
(MET-min/week) 
C 
W 
Mean 
1,295±1,606 
1,037±1,372 
1,158±1,477 
1,081±876 
1,432±2,406 
1,267±1,842 
1,625±1,691 
1,427±1,839 
1,573±1,754 
1,446±1,787 
1,205±1,544 
1,318±1,650 
G = 0.85 
T = 0.49 
I= 0.65 
Vigorous PA  
(MET-min/week) 
C 
W 
Mean 
437±791 
137±313 
278±602 
1,033±1,208d 
598±1,008d 
803±1,117d 
1,281±937d 
637±943d 
940±986d 
928±460d 
341±670 
617±647d 
G =0.002 
T=0.001 
I = 0.61 
Total PA 
(MET-min/week) 
C 
W 
Mean 
2,341±1,950 
1,825±2,028 
2,068±1,989 
3,334±2,228d 
2,879±3,228 
3,093±2,785d 
4,053±2,671d 
3,703±3,687d 
3,868±3,222d 
3,805±2,764d 
2,970±3,055 
3,363±2,923d 
G = 0.37 
T = 0.001 
I= 0.93 
Job PA 
 (MET-min/week) 
C 
W 
Mean 
1,230±1,713 
460±1,132 
822±1,472 
1,157±1,999 
751±1,332 
942±1,674 
1,465±1,936 
1,341±2,504 
1,400±2,233 
1,526±2,334 
640±1,443 
1,057±1,946 
G = 0.18 
T = 0.19 
I= 0.45 
Transportation PA 
(MET-min/week) 
C 
W 
Mean 
274±389 
129±294 
197±346 
311±450 
183±545 
243±501 
419±636 
477±878 
450±767d 
523±1,003 
820±1,528d 
680±1,303d 
G = 0.44 
T = 0.05 
I = 0.59 
House PA 
(MET-min/week) 
C 
W 
Mean 
594±882 
876±1,251 
743±1,092 
627±532 
1,262±2,279 
963±1,712 
1,133±1,500 
873±1,124 
996±1,308 
670±601 
950±1,388 
818±1,090 
G = 0.36 
Tq = 0.56 
I = 0.26 
Recreation PA  
(MET-min/week) 
C 
W 
Mean 
439±577 
340±549 
387±559 
1,259±593d 
746±958 
987±840d 
1,036±275d 
868±1,321d 
947±974d 
995±492d 
421±481 
691±561d 
G = 0.01 
T = 0.001 
I = 0.20 
aInternational Physical Activity Questionnaire (IPAQ) data were analyzed at 0, 4, 10, and 16 weeks of program participation for 
24 participants in the C group and 27 participants in the W group (n=51).   
bPA=physical activity. 
cMet-min/week=MET level x minutes of activity per day x days per week. 
dp<0.05 difference from baseline. 
eG=group alpha level. 
fT=time alpha level. 
gI=group x time interaction alpha level. 
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Table 6 shows changes in physical activity observed at 0, 4, 10, and 16 weeks of 
program intervention. Overall MANOVA revealed a significant time effects (Wilks’ 
Lamda p=0.001) with a trend in overall time by diet interaction observed (Wilks’ Lamda 
p=0.08) in physical activity variables.  Both groups increased total recreational activity  
(C 818±852, 597±549, 556±680; W 407±1052, 528±1082, 82±707 MET-min/week;  
p=0.20) with an effect of group observed (p=0.01) indicating total recreational activity 
was greater in the C group. Vigorous physical activity also increased in both groups (C 
595±666, 845±1059, 491±943; W 462±1026, 500±1028, 204±763 MET-min/week, 
p=0.61) with the C group increasing vigorous activity to a greater degree than the W 
group (p=0.002). Both groups increased total physical activity (C 993±2148, 
1712±2275, 1464±1775; W 1054±3519, 1878±2689, 1145±3215 MET-min/week; 
p=0.93) with no differences observed between groups. The W group increased low 
physical activity (C 143±1075, 49±1001, 273±1139; W 187±1501, 764±1454, 725±1806 
MET-min/week) and transportation physical activity (C 37±278, 145±530, 249±948; W 
54±558, 349±893, 691±1562 MET-min/week) with no significant difference observed  
between groups (p=0.27) and (p=0.33) respectively.  Large standard deviations revealed 
considerable variability in the physical activity levels of study participants. 
Body Composition, Anthropometry and Resting Energy Expenditure 
 Table 7 presents changes in body composition, anthropometry, and resting 
energy expenditure data observed at 0, 4, 10 and 16 weeks of program participation.   
MANOVA analysis of body composition data revealed overall time (Wilks’ Lamda 
p=0.001) and time by diet effects (Wilks’ Lamda p=0.003).  MANOVA Univariate 
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analysis revealed that both groups lost a similar amount of total mass (C -2.4±2.0, -
4.1±3.4, -5.1±3.9; W -2.3±2.3, -4.5±3.0, -5.5±4.6 kg, p=0.78).  Lean tissue mass was 
 
Table 7.  Changes in body composition, resting energy expenditure, and fitness related data values 
observed at 0, 4, 10 and 16 weeks of program participation for the Curves (C) and Weight Watchers 
(W) groupsa   
                                                                     Week  
Variable Group 0 4 10 16 p-value 
                                    mean±standard deviation  
Total Mass 
(kg) 
C  
W 
Mean 
84.5±15.0 
82.8±12.7 
83.6±13.7 
82.1±13.8b 
80.5±13.2b 
81.3±13.4b 
80.4±13.0b 
78.3±13.4b 
79.3±13.1b 
79.4±13.0b 
77.3±14.1b 
78.3±13.5b 
Gc =0.62 
Td=0.001 
Ie= 0.78 
Fat Mass  
(kg) 
C 
W 
Mean 
40.9±10.5 
37.4±9.1 
39.1±9.9 
37.0±8.1b 
37.0±8.7 
37.0±8.4b 
36.2±8.4b 
35.3±10.5 
35.8±9.4b 
34.5±8.5b 
34.5±10.7b 
34.5±9.6b 
G = 0.67 
T =0.001 
I = 0.09 
Lean Mass  
(kg) 
C 
W 
Mean 
43.6±7.8 
45.3±8.7 
44.5±8.2 
45.1±7.6 
43.5±7.2 
44.3±7.4 
44.1±7.0 
42.9±6.5b 
43.5±6.7 
44.9±6.7 
42.8±6.2b 
43.8±6.5 
G =0.68 
T = 0.32 
I = 0.01 
Body Fat  
(%) 
C 
W 
Mean 
48.1±6.5 
45.1±7.3 
46.5±7.1 
44.8±4.7b 
45.7±5.6 
45.3±5.2 
44.8±5.6b 
44.5±7.3 
44.7±6.5 
43.4±5.4b 
43.7±6.7 
43.5±6.1b 
G = 0.74 
T= 0.007 
I= 0.10 
BMIf   
(kg/m2) 
C 
W 
Mean 
34.1±5.1 
33.9±5.1 
34.0±5.1 
33.2±4.8b 
32.9±5.2b 
33.0±5.0b 
32.5±4.6b 
31.9±5.2b 
32.3±4.5b 
32.2±4.5b 
31.6±5.5b 
31.9±5.0b 
G = 0.75 
T= 0.007 
I = 0.24 
Waist  
(cm) 
C 
W 
Mean 
96.7±12.3 
93.2±8.6 
94.4±10.5 
92.9±11.4b 
92.3±11.3b 
92.6±11.2b 
90.3±10.1b 
89.8±10.6b 
89.9±10.5b 
89.6±10.2b 
87.9±10.7b 
88.7±10.4b 
G = 0.64 
T= 0.001 
I = 0.46 
Hip  
(cm) 
C 
W 
Mean 
120.8±10.2 
120.5±10.9 
120.6±10.4 
118.4±10.3b 
118.9±10.8b 
118.7±104b 
115.4±9.3b 
115.7±11.1b 
115.6±10.2b 
114.7±9.3b 
113.3±12.0b 
114.0±10.7b 
G = 0.98 
T =0.001 
I = 0.31 
REE 
(kcals/d) 
C 
W 
Mean 
1,389.1±252.5 
1,361.3±257.6 
1,374.4±253.0 
1,465.5±191.9 
1,415.3±200.4 
1,438.9±196.1b 
1,507.7±195.6b 
1,425.9±190.2b 
1,464.4±195.2b 
1,507.1±223.2b 
1,418.4±244.2b 
1,460.1±236.5b 
G = 0.34 
T =0.002 
I = 0.22 
aData are from 24 participants in the C group and 27 participants in the W group (n=51) who completed the 16-week study.   
 bp<0.05 difference from baseline. 
cG=group alpha level. 
dT=time alpha level. 
eI=group x time interaction alpha level. 
fBMI = body mass index. 
gResting Energy Expenditure 
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maintained in the C group and decreased in the W group (C 1.5±4.3, 0.52±3.7, 1.3±4.0; 
W -1.8±5.4, -2.4±5.8, -2.5±5.1, p=0.01). The C group tended to have a greater reduction 
in percent body fat (C -3.3±5.2, -3.2±4.6, -4.7±5.4; W 0.6±6.7, -0.6±8.3, -1.4±8.1 %, 
p=0.10) and fat mass (C -3.9±5.5, -4.6±5.3, -6.4±5.9; W -0.4±5.7, -2.1±6.7, -2.9±7.8, 
p=0.09).  Review of body composition data lead to acceptance H1 and a partial rejection 
of H01.   
 MANOVA analysis of anthropometry data revealed an overall time effect 
(Wilks’ Lamda p=0.001) effect with no significant overall time by diet effect (p=0.18).   
After 16 weeks both groups had decreased BMI (C -0.9±0.8, -1.6±1.3, -1.8±1.4; W - 
1.0±0.5, -2.0±0.9, -2.3±1.5 kg/m2; p=0.24), waist circumference(C -2.8±3.7, -5.4±5.4, - 
6.2±5.1; W -0.9±5.7, -3.8±6.0, -5.4±5.2 cm; p=0.46) and hip circumference (C -2.1±2.6, 
-5.0±4.2, -5.8±5.0; W -1.8±4.0, -5.1±3.7, -7.4±4.9 cm; p=0.31), with no differences 
observed.  Univariate ANOVA revealed both groups had an increase in resting energy 
expenditure (REE) (C 76.4±195.7, 118.6±185.5, 118.0±162.5; W 53.9±187.9, 
64.6±188.9, 57.0±216.6 kcals/d, p=0.54) with no difference observed between groups 
and lead to a rejection of H2. 
Resting Heart Rate and Blood Pressure 
Table 8 presents resting heart rate (RHR), resting systolic blood pressure (BP), and 
resting diastolic blood pressure observed at 0, 4, 10 and 16 weeks and changes in 
cardiorespiratory and muscular fitness after 16 weeks of program participation.  
MANOVA analysis of RHR and BP data revealed an overall time effect (Wilks’ Lambda 
p=0.001) effect with no overall time by diet interaction effect (Wilks’ Lambd p=0.22).  
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The C group experienced reductions in RHR (C -4.6±9.3, -5.9±10.7, -1.0±8.8; W -
5.2±12.4, -1.0±12.1, -2.0±14.1 bpm, p=0.17) with no differences observed between 
groups. Both groups experienced similar changes in resting systolic BP (C -3.3±7.8, -
3.8±11.1, -5.0±11.2; W -5.5±10.1, -4.9±11.9, -5.3±8.9 mmHg, p=0.86) and resting 
diastolic BP (C -4.1±8.0, -1.8±10.1, -1.5±10.1; W -4.3±8.8, -5.4±9.4, -4.7±7.9 mmHg, 
p=0.32) with no differences observed between groups.  Review of resting cardiovascular 
data lead to an acceptance of H02.   
Cardiorespiratory and Muscular Endurance and Fitness 
MANOVA analysis of peak VO2 and treadmill time revealed an overall time effect 
(p=0.001) with no overall time by diet (p=0.12) effect observed. Univariate ANOVA 
analysis revealed both groups experienced an increase in peak oxygen uptake in L/min  
(C 0.09±0.16; W 0.03±0.13 L/min, p=0.13), peak oxygen uptake in ml/kg/min (C 
2.4±2.3; W 2.1±2.0 ml/kg/min, p=0.68) and treadmill time (C 0.61±0.76; W 0.72±1.22 
min, p=0.71) with no differences observed between groups after 16 weeks of program 
participation. Consideration of peak V02 and treadmill time data lead to a rejection of 
H3.   
 MANOVA analysis of muscular fitness and endurance changes from 0 to 16 
weeks revealed an overall time x diet effect (Wilks’ Lambda p=0.01) with no overall 
time effect (Wilks’ Lambda p=0.99). No significant changes were observed in either the 
C group or W group in leg press 1 RM (C 8.4±29.6; W -4.6±30.3 kg, p=0.13), bench  
press 1RM (C 1.1±4.7; W -0.7±3.8 kg; p=0.13), or leg press lifting volume at 80% 1 RM 
(C 131.3±925.3; W -56.1±1119.5 reps*kg; p=0.52).  One way ANOVA revealed the C 
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Table 8.  Changes in general health and fitness values obtained at 0, 4, 10 and 16 weeks of program 
participation for the Curves (C) and Weight Watchers (W) groupsa  
 
                                                          Week 
 
Variable Group 0 4 
 
10 
 
16 p-value 
                                   mean±standard deviation  
 
Resting Heart Rate  
 (bpm) 
 
C 
W 
Mean 
 
72.5±8.5 
70.0±9.1 
71.2±8.8 
 
67.9±8.4b 
65.8±8.1b 
66.3±8.3b 
 
66.6±9.2b 
69.0±7.1 
67.9±8.1b 
 
71.5±8.5 
68.0±8.7 
69.7±8.7 
 
Gc = 0.27 
Td=0.008 
Ie= 0.17 
Resting Systolic BPf  
(mmHg) 
C 
W 
Mean 
120.5±11.4 
118.4±9.6 
119.4±10.4 
117.2±8.5b 
112.9±9.4b 
114.9±9.2b 
116.7±13.3 
113.6±7.3b 
115.1±10.6
b 
115.5±12.5b 
113.2±8.7b 
114.3±10.6b 
G = 0.20 
T= 0.003 
I= 0.86 
Resting Diastolic BP 
(mmHg) 
C 
W 
Mean 
75.5±8.5 
77.9±6.3 
76.8±7.5 
71.4±9.0b 
73.6±7.7b 
72.6±8.3b 
73.8±8.4 
72.5±7.0b 
73.1±7.6b 
74.0±11.5 
73.2±6.5b 
73.6±9.1b 
G = 0.72 
T = 0.005 
I= 0.32 
Peak VO2
g  
(L/min) 
C 
W 
Mean 
2.0±0.4 
2.0±0.3 
2.0±0.3 
  2.0±0.4b 
2.1±0.3b 
2.1±0.4b 
G = 0.42 
T = 0.005 
I = 0.13 
Peak VO2
g  
(ml/kg/min) 
C 
W 
Mean 
23.0±4.2 
22.7±3.7 
22.8±3.9 
  25.3±4.4b 
24.8±4.5b 
25.1±4.4b 
G = 0.74 
T = 0.001 
I = 0.68 
Treadmill Time 
(min) 
C 
W 
Mean 
7.9±1.2 
7.8±1.5 
7.8±1.4 
  8.5±1.5b 
8.5±1.2b 
8.5±1.3b 
G=0.72 
T=0.001 
I=0.71 
Bench Press  
1 RMh (kg) 
C 
W 
Mean 
34.4±7.6 
34.5±9.4 
34.5±8.5 
  35.5±70 
33.8±8.4 
34.6±7.8 
G = 0.13 
T = 0.70 
I = 0.13 
Bench Lifting Volumei  
(repetitions*kg) 
C 
W 
Mean 
156.0±77.2j 
218.7±107.1 
189.2±98.5 
  196.2±93.8bj 
179.6±89.0b 
187.4±90.7 
G = 0.002 
T = 0.97 
I = 0.002 
Leg Press 1 RM (kg) C 
W 
Mean 
196.0±57.3 
200.0±67.7 
198.1±61.9 
  204.4±56.4 
195.3±65.6 
199.6±61.0 
G = 0.88 
T = 0.65 
I = 0.13 
Leg Lifting Volumek       
(repetitions*kg) 
C 
W 
Mean 
1857.2±1018.7 
2057.7±1103.3 
1954.0±1059.6 
  1968.5±1040.4 
2001.6±1235.5 
1986.0±1136.6 
G = 0.65 
T = 0.80 
I = 0.52 
aData are from 24 participants in the C group and 27 participants in the W group (n=51) who completed the 16-week study.   
bp<0.05 difference from baseline. 
cG=group alpha level 
dT=time alpha level 
eI=group x time interaction alpha level 
fBlood Pressure 
 gPeak VO2 = peak oxygen uptake. 
h1 RM = 1 repetition maximum 
iBench press lifting volume at 80% 1 RM (kg) 
jp<0.01 difference between C and W groups. 
kLeg Press lifting volume at 80% 1 RM (kg) 
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group had a significantly lower baseline bench press lifting volume at 80% 1 RM 
(p=0.02).  Univariate analysis of changes from baseline revealed participants in the C 
group had a moderate increase in bench press endurance at 16 weeks, while the W group 
displayed a decreased endurance (C 40.2±104.1; W -39.1±65.4 reps*kg) with effects of 
group (0.002) and time by diet (p=0.002) observed.  Review of overall muscular strength 
and endurance data lead to a partial acceptance of H4.  
Biochemical Markers of Health 
Table 9 presents changes in Fasting blood lipid values observed at 0, 4, 10 and 16 weeks 
of program participation.   An overall MANOVA of fasting lipids revealed a time effect 
(Wilks’ Lamda p=0.001) with no significant overall MANOVA time x diet interactions 
(Wilks’ Lamda p=0.21).  MANOVA Univariate analyses were conducted on percent 
changes from baseline. Both groups experiences a decrease in CHL, with no differences 
observed between groups (C -6.1±11.0, -4.1±7.4, -2.3±9.5; W -6.8±9.4, -5.7±12.6, -
6.3±13.0 %, p=0.49).  LDL-c levels decreased in the W group with no differences 
observed between groups (C -6.9±17.3, -2.7±13.6, -4.6±17.2; W -5.6±14.5, -2.8±19.7, -
11.4±15.9 %, p=0.31). The C group had a moderate increase in HDL-c, while the W 
group experienced a decrease in HDL-c at 4 and 10 weeks (C -2.1±12.5, 3.0±12.3, 
5.9±18.3; W -9.5±11.5, -9.5±12.7, -1.6±14.6 %) with time by diet (p=0.03) and diet 
(p=0.005) effects observed leading to rejection of H04.  The W group experienced an 
increase in the CHL:HDL ratio at 10 weeks (C -1.8±13.1, -4.0±10.1, -3.8±12.2; W 
3.4±13.4, 5.3±12.5, -3.4±14.2 %) time by diet effect (p=0.04) and trend in diet effect 
(p=0.08) observed.  The C group tended to experience greater reductions in TG levels, 
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with an effect of diet observed (p=0.06) (C -8.0±26.3, -11.7±18.0,-2.3±26.1; W 4.0± 
25.2, 5.0±32.1, 7.8±52.4 %).  Consideration of overall lipid biomarker data lead to a 
partial acceptance of H03. 
 
Table 9.  Fasting blood lipid values obtained at 0, 4, 10 and 16 weeks of program participation for the 
Curves (C) and Weight Watchers (W) groupsa  
                                               Week  
Variable Group 0 4 10 16 p-value 
                               
                                 mean±standard deviation 
 
Total Cholesterol 
(CHL) (mg/dl)b 
C 
W 
Mean 
174.63±30.29 
186.07±29.51 
180.69±30.17 
163.54±31.47c 
172.40±26.50c 
168.23±29.00c 
167.22±31.35c 
174.67±30.97c 
171.16±31.06c 
170.67±33.15 
173.47±30.22c 
172.10±31.34c 
Gd= 0.34 
Te=0.001 
If= 0.42 
LDL Cholesterol   
(mg/dl) 
C 
W 
Mean 
97.67±25.97 
110.00±26.08 
104.20±26.50 
90.54±28.83 
102.54±24.15c 
96.89±26.87c 
94.04±25.07 
105.07±25.48 
99.88±25.65 
92.88±28.07 
95.72±21.86c 
94.38±24.80c 
G = 0.36 
T= 0.001 
I = 0.15 
HDL Cholesterol 
(mg/dl) 
C 
W 
Mean 
51.71±15.07 
52.11±14.05 
51.92±14.39 
49.72±11.98 
46.80±12.78c 
48.18±12.37c 
52.66±14.15g 
46.44±11.53c 
49.37±13.08c 
54.25±16.38 
50.78±13.98 
52.41±15.10 
G = 0.41 
T= 0.001 
I= 0.02 
Triglyceridesh 
(mg/dl) 
C 
W 
Mean 
125.58±58.51 
120.00±43.88 
122.63±50.83 
113.00±58.15 
122.22±48.62 
117.88±52.97 
108.85±49.36c 
121.85±53.35 
115.73±51.37 
123.54±63.40 
130.56±98.60 
127.25±83.17 
G = 0.70 
T = 0.32 
I= 0.51 
CHL/HDL 
ratio 
C 
W 
Mean 
3.8±1.0 
3.6±1.1 
3.7±1.0 
3.5±0.9 
3.9±1.0 
3.7±1.0 
3.4±0.9g 
4.0±1.1c 
3.7±1.0 
3.4±1.0 
3.6±1.2 
3.5±1.1 
G = 0.24 
T = 0.19 
I= 0.08 
aLipid data were obtained at 0, 4, 10 and 16 weeks on 24 participants in the C group and 27 participants in the W group (n=51) 
completing the 16-week weight loss program.  
bTo convert mg/dL cholesterol to mmol/L, multiply mg/dL by 0.026.  To convert mmol/L cholesterol to mg/dL, multiply 
mmol/L by 38.6.  Cholesterol of 194 mg/dl=5.04 mmol/L. 
cp<0.05 difference from baseline. 
dG=group alpha level. 
eT=time alpha level. 
fI=group x time interaction alpha level. 
gp<0.01 difference between C and W groups. 
hTo convert mg/dL triglyceride to mmol/L, multiply mg/dL by 0.0113.  To convert mmol/L triglyceride to mg/dL, multiply 
mmol/L by 88.6.  Triglyceride of 137 mg/dl=1.55 mmol/L. 
 
 
 
Table 10 presents changes in fasting glucose, insulin, HOMA and leptin values observed 
at 0, 4, 10 and 16 weeks of program participation. MANOVA analysis of fasting glucose 
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and insulin related variables revealed no overall Wilks’ Lamda significant diet (p=0.18), 
or time by diet (p=0.44) effects.  Univariate MANOVA analyses of percent changes in 
 
Table 10.  Fasting glucose, insulin and leptin values obtained at 0, 4, 10 and 16 weeks of program 
participation for the Curves (C) and Weight Watchers (W) groupsa  
                                                Week  
Variable Group 0 4 10 16 p-value 
      
                                 mean±standard deviation 
 
Glucoseb 
(mg/dl) 
C 
W 
Mean 
91.50±15.10 
89.07±9.35 
90.22±12.32 
88.69±13.51 
89.23±7.81 
88.97±10.76 
90.75±19.45 
87.37±5.52 
88.96±13.89 
87.88±16.24 
89.04±6.79 
88.49±12.07 
Gc = 0.74 
Td = 0.59 
Ie = 0.30 
Insulinf 
(IU/ml) 
 
C 
W 
Mean 
20.48±12.14g 
10.99±4.67 
15.46±10.10 
15.86±7.01 
10.65±4.37 
13.10±6.28 
14.54±7.40 
11.17±6.40 
12.76±7.03 
16.08±8.15 
10.60±5.47 
13.18±7.33 
G = 0.15 
T=0.63 
I = 0.47 
Glucose/Insulin 
Ratio 
 
C 
W 
Mean 
9.0±12.3 
9.5±4.0 
9.3±8.8 
9.5±14.3 
10.34±7.5 
9.4±10.0 
9.0±7.5 
11.7±9.8 
10.4±8.8 
11.5±23.5 
15.5±24.9 
13.7±24.1 
G =  0.94 
T= 0.69 
I = 0.22 
HOMAh C 
W 
Mean 
4.71±3.04g 
2.40±1.01 
3.49±2.48 
3.44±1.49 
2.35±0.93 
2.86±1.33 
3.23±1.62 
2.40±1.36 
2.80±1.53 
3.56±2.03 
2.35±1.24 
2.92±1.75 
G = 0.12 
T = 0.81 
I= 0.79 
Leptinl 
ng/ml 
C 
W 
Mean 
66.28±26.66i 
51.35±22.00 
58.38±25.21 
53.05±26.30 
46.76±27.15 
49.72±26.67 
42.11±26.68j 
45.48±34.62 
43.90±30.88 
52.70±25.10 
42.30±29.49 
47.20±27.74 
G = 0.45 
T = 0.37 
I = 0.08 
aGlucose, insulin, and leptin data were obtained at 0, 4, 10 and 16 weeks on 24 participants in the C group and 27 participants 
in the W group (n=51) completing the 16-week weight loss program.  
bTo convert mg/dL glucose to mmol/L, multiply mg/dL by 0.0555.  To convert mmol/L glucose to mg/dL, multiply mmol/L by 
18.0.  Glucose of 99 mg/dl=5.5 mmol/L. 
cG=group alpha level. 
dT=time alpha level. 
eI=group x time interaction alpha level. 
fTo convert µIU/ml insulin to pmol/L, multiply µIU/ml by 6.945.  To convert pmol/L to µIU/ml, multiply pmol/L by 0.144.  
Insulin of 13.8 µIU/ml=95.8 pmol/L. 
gp<0.01 difference between C and W groups. 
hHomeostatic Model Assessment 
ip<0.05 difference between C and W groups. 
jp<0.05 difference from baseline. 
 
 
 
glucose and glucose-to-insulin ratios revealed neither group experienced significant 
changes in glucose (p=0.30) or glucose-to insulin ratios (p=0.30). One way ANOVA 
analysis revealed higher insulin and HOMA values in the C group at baseline (insulin, 
 72 
 
p=0.001; HOMA, p=0.001).  Univariate ANCOVA revealed neither group experienced 
significant changes in fasting insulin levels (p=0.47) or HOMA (p=0.79.  Large standard 
deviations revealed considerable variability in study participant insulin levels.  Review 
of glucose related variables resulted in acceptance of H05.  One way ANOVA revealed 
higher leptin levels in the C group at baseline (p=0.03).  Univariate ANCOVA revealed 
The C group tended to have greater reductions in leptin when compared to the W group 
(C -13.24±21.77, -24.17±31.00, -13.58±25.45; W -4.59±20.15, -5.86±27.60, -
9.04±28.97 ng/ml, p=0.08).  
Psychosocial 
Table 11 presents changes in psychosocial values observed at 0, 4, 10 and 16 weeks of 
program participation as determined by the SF36 Quality of Life Inventory.  MANOVA 
analysis of SF36 quality of life indices revealed an overall time effect (Wilks’ Lamda 
p=0.001) with no significant overall time x diet interactions observed (p=0.11).  
Univariate MANOVA analysis revealed the C group tended to have a greater increase in 
vitality than the W group (C 8.96±8.84, 12.24±10.64, 10.00±11.33; W 8.06±9.9, 
5.09±12.72, 9.35±14.99) with trends in time by diet (p=0.10) and diet effects (p=0.10)  
observed. Both programs increased ratings of emotion (C 5.50±7.47, 10.41±10.74, 
10.58±8.95; W 7.26±10.11, 8.74±13.81, 6.07±14.35, p=0.18) bodily pain (C 8.58±18.23, 
8.63±20.01, 11.38±20.39; W 6.96±13.25, 5.85±15.81, 7.37±14.64, p=0.72) and general 
health (C 6.67±10.72, 9.36±12.13, 7.54±12.83; W 4.37±10.63, 4.70±13.20, 6.11±12.50, 
p=0.41) with no differences observed between groups.  The C group experienced  
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Table 11.  Changes in SF36 Quality of Life Inventory values observed at 0, 4, 10 and 16 weeks of 
program participation for the Curves (C) and Weight Watchers (W) groupsa   
                                           Week  
Variable Group 0 4 10 16 p-value 
                               
                           mean±standard deviation 
 
 
Physical Fitness 
 
C 
W 
Mean 
88.54±12.72b 
78.15±21.53 
83.04±18.52 
91.67±9.05 
88.33±13.16 
89.90±11.42 
94.05±6.38 
90.56±12.66 
92.20±10.25 
94.58±8.59 
90.00±14.48 
92.16±12.18 
Gc=0.63 
Td=0.14 
Ie=0.73 
Role Physical 
 
C 
W 
Mean 
342.71±83.14 
337.04±87.26 
339.71±84.58 
370.83±53.50 
344.44±72.50 
356.86±65.02 
374.45±46.73 
346.30±76.81 
359.50±65.36 
373.96±51.33 
354.63±66.88 
363.73±60.2f 
G=0.22 
T=0.06 
I=0.55 
Role Emotional 
 
C 
W 
Mean 
337.74±69.31 
329.51±74.20 
333.38±71.35 
351.33±69.53 
341.91±61.76 
346.35±65.04 
371.73±46.96f 
345.64±81.21 
357.92±67.95f 
377.75±44.6f 
344.42±83.74 
360.10±69.6f 
G=0.18 
T=0.06 
I = 0.51 
Vital 
 
 
C 
W 
Mean 
51.88±12.75 
48.98±12.56 
50.34±12.61 
60.83±11.86bf 
57.04±11.29f 
58.82±11.60f 
64.12±9.88gf 
54.07±15.51f 
58.80±11.60f 
61.88±10.82bf 
58.33±16.41f 
60.00±14.04f 
G=0.10 
T=0.001 
I= 0.10 
Emotion 
 
C 
W 
Mean 
56.08±13.14 
52.74±11.74 
54.31±12.41 
61.58±11.24f 
60.00±9.67f 
60.75±10.36f 
66.49±9.79f 
61.48±12.46f 
63.84±11.45f 
66.67±8.80f 
58.81±13.49f 
62.51±12.08f 
G=0.10 
T=0.001 
I= 0.18 
Social C 
W 
Mean 
49.19±6.88 
49.52±7.37 
49.36±7.08 
49.46±8.66 
50.00±4.90 
49.75±6.86 
47.90±7.96 
50.93±3.34 
49.50±6.10 
50.00±3.69 
49.54±6.45 
49.76±5.29 
G=0.36 
T=0.96 
I=0.51 
Bodily Pain C 
W 
Mean 
70.63±17.14 
69.37±15.56 
69.96±16.17 
79.21±11.89f 
76.33±13.31 
77.69±12.62c 
79.26±11.32f 
75.22±15.93f 
77.12±13.97f 
82.00±10.69f 
76.74±14.61f 
79.22±13.06f 
G=0.28 
T=0.001 
I =0.72 
General Health 
 
C 
W 
Mean 
67.79±16.38 
65.81±14.97 
66.75±15.52 
74.46±13.58f 
70.19±13.44 
72.20±13.54f 
77.15±12.81f 
70.52±13.55f 
73.64±13.49f 
75.33±13.56f 
71.93±15.68f 
73.53±14.68f 
G=0.26 
T=0.001 
I =0.41 
a SF36 Quality of Life Inventory data were analyzed at 0, 4, 10, and 16 weeks of program participation for 24 participants in the 
C group and 27 participants in the W group (n=51).   
bp<0.05 difference between C and W groups. 
cG=group alpha level. 
dT=time alpha level. 
eI=group x time interaction alpha level. 
fp<0.05 difference from baseline. 
gp<0.01 difference between C and W groups. 
 
increases in the role emotional rating (C 13.60±75.8, 34.00±63.50, 40.01±69.99; W 
12.41±69.31, 16.14±80.26, 14.01±69.99, p=0.24) with no differences observed between 
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groups.  Neither group experienced changes in ratings of role physical (p=0.55) or social 
(p=0.51).  One way ANOVA revealed the C group rated physical fitness higher than the 
W group at baseline (p=0.05). Univariate ANCOVA revealed neither group experienced 
significant changes in rating of physical fitness (p=0.85). Large standard deviations  
revealed considerable variability between study participant ratings of SF36 indices. 
Consideration of overall psychosocial data resulted in a partial rejection of H06. 
Eating Satisfaction 
Table 12 depicts changes in eating satisfaction observed at 0, 4, 10 and 16 weeks of 
program participation. Overall MANOVA analysis of eating satisfaction indices 
revealed a significant time effect (Wilks’ Lamda p=0.001) with a trend in time by diet 
effect observed (Wilks’ Lamda p=0.06).  Feelings of fullness decreased in the W group 
(C 0.42±1.93, 0.01±1.75, 0.54±1.44; W -0.81±1.8, -0.67±1.9, -0.78±1.5, p=0.02). One 
way ANOVA revealed the W group rated food quality lower at baseline than the C 
group (ANOVA p=0.05). Univariate ANCOVA revealed neither group experienced 
significant changes in food quality (p=0.52). Neither the C group nor the W group 
experienced changes in hunger (p=0.51) or food satisfaction scores (p=0.68). Both the C 
group and W group experienced increases in energy (C 1.83±1.81, 1.23±2.0, 2.00±2.04; 
W 1.30±1.84, 1.63±1.78, 1.26±1.9, p=0.41) and decreases in appetite (C -0.83±1.49, -
0.61±1.40, -0.50±1.50; W -0.48±1.45, -0.93±2.11, -0.44±1.45, p=0.72). 
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Table 12.  Changes in eating satisfaction values observed at 0, 4, 10 and 16 weeks of program participation for 
Curves (C) and Weight Watchers (W) groupsa   
                                              Week  
Variable Group 0 4 10 16 p-value 
   
                                mean+standard deviation 
 
 
 
Appetite 
 
 
C 
W 
Mean 
 
6.17±1.20 
6.00±1.73 
6.08±1.94 
 
5.33±1.17b 
5.52±1.25 
5.43±1.20b 
 
5.55±1.56b 
5.07±1.17b 
5.20±1.38b 
 
5.67±1.43 
5.56±1.25 
5.61±1.33b 
 
Gc= 0.62 
Td=0.003 
Ie=0.45  
Hunger  C 
W 
Mean 
5.33±1.58 
5.07±0.98 
5.20±1.30 
5.08±1.50 
5.00±1.44 
5.04±1.46 
5.08±1.91 
4.81±1.36 
4.94±1.63 
5.25 ±1.57 
 5.37±1.60 
 5.31±1.60 
 G = 0.70 
 T= 0.38 
I= 0.80 
Satisfied 
food 
 
C 
W 
Mean 
6.59±1.47 
6.19±1.62 
6.37±1.55 
6.13±1.33 
6.07±1.69 
6.10±1.51 
6.30±1.68 
6.07±1.60 
6.18±1.62 
6.21±1.91 
6.04±1.40 
6.12±1.64 
G =0.52 
T=0.64 
I= 0.90 
Fullness 
 
C 
W 
Mean 
6.08±1.53 
6.63±1.18 
6.37±1.37 
6.5±1.44f 
5.81±1.69b 
6.14±1.60 
6.08±1.53 
5.96±1.34 
6.02±1.42 
6.63±1.53f 
5.85±1.51b 
6.23±1.55 
G =0.36 
T=0.58 
I = 0.04 
Energy 
 
 
C 
W 
Mean 
5.13±1.73 
4.52±1.72 
4.80±1.73 
6.96±1.33b 
5.81±1.44b 
6.35±1.49b 
6.39±1.58b 
6.15±1.59b 
6.26±1.57b 
7.13±1.65b 
5.78±1.80b 
6.41±1.85b 
G = 0.02 
T=0.001 
I= 0.12 
Quality 
  
C 
W 
Mean 
4.58±2.15g 
3.56±1.50 
4.04±1.89 
6.48±1.25 
6.48±1.34 
6.48±1.28 
6.39±1.31 
6.41±1.40 
6.40±1.34 
7.08±1.59 
6.11±1.45 
6.57±1.58 
G = 0.83 
T = 0.04 
I= 0.52 
aEating Satisfaction Questionnaire data were analyzed at 0, 4, 10, and 16 weeks of program participation for 24 participants 
in the C group and 27 participants in the W group (n=51).   
bp<0.05 difference from baseline. 
cG=group alpha level. 
dT=time alpha level. 
eI=group x time interaction alpha level. 
fp<0.05 difference between C and W groups. 
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CHAPTER V 
SUMMARY 
 
The alarming rise in the prevalence of obesity, along with the direct and indirect costs of 
the disease, has caused much emphasis to be placed on finding efficacious weight loss 
interventions.  A multitude of industry-sponsored commercial weight loss programs have 
emerged that are marketed as producing significant weight loss in overweight or obese 
individuals.  Many of these programs are based on scientifically proven weight loss 
strategies such a following a nutritionally sound reduced kilocalorie diet plan, 
consuming nutritious prepared meals or meal replacements, providing physical activity 
recommendations or facilitating participation in a supervised exercise program, and/or 
behavior modification. Conducting comparative effectiveness trials on commercial 
programs that utilize proven weight loss strategies will reveal the relative efficacy, 
safety, and value of these programs 195, 196.  Our investigation compared the efficacy of 
the Curves® Fitness and Weight Management Plan to the Weight Watchers® 
Momentum™ Plan on body composition and markers of health and fitness in previously 
sedentary obese women. 
 Few studies have investigated the efficacy of commercial weight loss programs 
on weight loss and markers of fitness and health in randomized controlled trials. Truby 
et al.45, 46 conducted a randomized controlled comparative effectiveness trial of 4 
commercially available weight loss diets over a period of 6 months. A commercial 
program based on regular weighing, advice about diet and physical activity, motivation 
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and group support; a commercial program based on a low fat diet plan and weekly 
exercise; a meal replacement plan, and a self-monitored low carbohydrate eating plan 
were investigated. All diets resulted in clinically meaningful weight loss (4.9-7.3 %) and 
fat loss (2.1-3.6 %) compared with a no diet control, -0.6 and -0.1 % respectively, with 
no differences observed between diets. Both of the commercial weight loss programs 
reduced plasma LDL-c. Additionally, the group support based commercial program and 
the self-monitored low carbohydrate plan lead to reduced TG at 6 months; however, 
LDL particle size was also increased following these interventions 45, 46.   
 In our investigation, the C group followed a structured higher protein meal-plan-
based cyclic diet plan while the W group followed a points centered diet plan that was 
based on weight, height, age, and activity level. The C group meal plan resulted in a 
similar average caloric intake as the W diet plan, with approximately 1,353±232 vs. 
1,356±232 kcalories/d consumed on average throughout the study.  The C group 
consumed a greater percentage of kcalories as protein (26±5 vs. 22±3 %), a higher 
percentage of kcalories as fat (34±5 vs. 30±5 %) and a lower percentage of kcalories as 
carbohydrate (39±8 vs. 47± 6%) in comparison to the W group. Though participants in 
both the C group and W group increased total physical activity 3,731±2,214 vs. 
3,184±2,485 MET-min/week, participants in the C group increased recreational activity 
to a greater extent (1,097±273 vs. 678±646 MET-min/week) than the W group. 
Furthermore, the C group performed circuit resistance-training interspersed with a low-
impact calisthenics three times each week, which resulted in a greater increase in 
vigorous activity 1,081±635 vs. 525±577 MET-min/week in comparison to the W group. 
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Both the C program and the W program resulted in similar levels of moderate physical 
activity 1,384±1,869 vs. 1,388±1,453 MET-min/week, job physical activity 1,382±1,869 
vs. 911±1,332 MET-min/week, house physical activity 810±633 vs. 1,028±1285 MET-
min/week, low physical activity 1,252±1,424 vs. 1,261±1,316 MET-min/week and 
transportation physical activity 417±619 vs. 493±737 MET-min/week; however, only 
the W group experienced an observable increases in low and transportation physical 
activity.    
 In our study, overall body composition changes were more favorable in the C 
group.  Both groups lost a similar amount of total mass over the 16 week study with the 
C group experiencing a loss of 5.1±3.9 kg (5.8±4.0 % decrease in body mass) and the W 
group having a reduction of 5.5±4.6 kg (6.9±5.8 % decrease in body mass).  However, 
the C group maintained lean tissue with a modest increase of 1.3±4.0 kg, while the W 
group had a reduction in lean mass of -2.5±5.1 kg.  The C group also tended to have a 
greater reduction in fat mass -6.4±5.9 vs. -2.9±7.8 kg and percent body fat -4.7±5.4 vs. -
1.4±8.1 % following the 16 week study. Both the C and W programs resulted in 
reductions in BMI -1.8±1.4 vs. -2.3±1.5 kg/m2, waist circumference -6.2±5.1 vs. -
5.4±5.2 cm and hip circumference -5.8±5.0 vs. -7.4 ±4.9 cm.  Our results are in 
agreement with a previous study conducted by Kreider and colleagues197, where the C 
program resulted in significant reductions in body mass, fat mass, BMI and waist 
circumference, while preserving muscle mass and other investigations where resistance 
based circuit training combined with calorically restricted high protein diets resulted in 
enhanced loss of body fat and preservation of lean body mass 33, 34.  As observed in our 
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investigation, previous trials have found the W program to be efficacious for the 
reduction of total body mass, body fat mass, BMI and waist circumference, though 
preservation of lean tissue mass has not been demonstrated 45, 198-200.  Our findings 
suggest adherence to a high protein meal-plan based diet and supervised resistance-
training exercises interspersed with a low-impact calisthenics exercise program is more 
effective in promoting positive body composition changes than a points based diet plan 
combined with education and encouragement to increase physical activity.  
 Both the C program and W program resulted in improvements in cardiovascular 
capacity.  The C group experienced a 5.2±10.1 % increase in peak VO2 in L/min and 
11.1±11.5 % increase in peak VO2 in ml/kg/min, while the W group experienced a 
1.3±6.6 % increase in peak VO2 in L/min and 9.3±8.5 % increase in ml/kg/min.  Both 
the C group and W group experienced decreases in RHR and diastolic BP during 
program participation; however, the W experienced a reduction in diastolic BP 
throughout the study and at 16 weeks (-1.5±10.1 vs. -4.7±7.9 mmHg).  Both the C group 
and W group experienced a decrease in resting systolic BP at 16 weeks (-5.0±11.2 vs. -
5.3±8.9 mmHg). Previous investigations have demonstrated reductions in blood pressure 
following participation in both the C program 35, 197 and W program 198, 200.  Both the C 
and W programs resulted in an increase in REE values by 9.7±12.8 vs. 5.7±18.0 % after 
16 weeks of program participation. We did not observe any changes in upper or lower 
body 1RM strength or lower body endurance in either the C group or the W group 
during our investigation. However, the W group experienced a decrease in upper body 
muscular endurance, while participants in the C group had an increase in bench press 
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repetitions at 80 % 1RM, -12.3±35.5 vs. 49.1±89.0 %. The increase in upper body 
endurance observed in the C groups was most likely a result of biweekly Zumba 
workouts, which emphasizes muscular endurance. Other trials evaluating changes in 
muscular strength and cardiovascular fitness following participation in the C program 
have observed significant increases in upper and lower body 1 RM strength and peak 
oxygen uptake at 2.5, 3.5 and 8.5 months of program participation 35, 197. Though we did 
not observe significant changes in 1RM strength in our investigation, this may be a result 
of greater upper and lower body 1RM strength at baseline in our study participants in 
comparison to other trials. Changes in muscular strength and fitness and cardiovascular 
endurance have not been evaluated in previous trials investigating the W program.  
 In our investigation, both the C group and W group had reductions in CHL after 
16 weeks of program participation, -2.3±9.5 vs. -6.3±13 %. The W group also 
experienced reductions in LDL-c levels at 16 weeks, -11.4±15.9 vs. -4.6±17.2 %. While 
the C group maintained HDL-c levels throughout the investigation, the W group 
experienced a -9.5±11.5 % reduction in HDL-c at 4 and 10 weeks and a 5.3±12.5 % 
increase in CHL:HDL ratio at 10 weeks.  The C group also experienced a -11.7±18.0 % 
reduction in TG levels at 10 weeks of program participation. Kersick and colleagues35 
examined changes in lipid panels after 3.5 months of participation in the C program’s 
resistance-based circuit training combined with calorically reduced diets of varying 
macronutrient composition. A high carbohydrate, low protein intake resulted in reduced 
CHL, while a low carbohydrate moderate protein meal plan resulted in reduced TG after 
14 weeks of program participation. All macronutrient combinations in combination with 
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the C program exercise plan maintained HDL-c levels 35. Other investigations have also 
shown a superior affect of elevated protein ingestion 23, 25, 29 and elevated protein 
combined with a supervised circuit training based programs 34 for the reduction of 
triglycerides while maintaining HDL-C 33.  Previous investigations of the W program 
have shown varying lipid panel changes following program intervention.  Bellise et al.200 
observed reductions in CHL and LDL-c with no changes in HDL-c, TG or in CHL:HDL-
c ratio after 3 months of program participation, while Morgan et al.46 observed decreased 
TG, LDL-c and HDL-c following 2-6 months of participation.  In contrast, Jebb and 
coworkers199 observed no significant changes in lipid panel values following 12 months 
of participation in the W program. We did not observe any changes in glucose, glucose 
to insulin ratio, insulin or HOMA following participation in either the C or W program. 
However, the C group tended to have greater reductions in leptin when compared to the 
W group -13.5±25.5 vs. -9.0±29.0 %. These results support previous findings that 
adherence to a meal plan based diet combined with weekly resistance-based circuit 
training can result in reductions in serum leptin levels35. The greater reduction in leptin 
may be directly related to the greater fat mass loss observed in the C group, as the 
concentration of leptin in plasma has been shown to parallel adipose tissue mass 99, 104.   
 Moderate weight loss has been associated with improved health related quality of 
life 142, 145.  Both the C program and W programs resulted in improved physical and 
mental health ratings following 16 weeks of program participation.  Both the C and W 
groups experienced increases in ratings of emotion (23.3±23.6 vs. 15.5±34.3%), bodily 
pain (24.8±42.3 vs. 13.9±25.0%), and general health (14.7±22.3 vs. 11.0±24.8%) at 16 
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weeks.  The C group tended to have a greater increase in vitality than the W group, 
24.4±30.8% vs. 22.3±36.1%, and also experienced an improvement the role emotional 
rating, 16.4±28.7% vs. 7.7±30.9%.  Other trials have found similar increases in vitality 
following participation in the C program 35, 197.  Feelings of fullness decreased in the W 
group following 16 weeks of program participation while remaining elevated in the C 
group, -11.1±27.9 vs. 13.2±30.5%. Feelings of fullness may have been maintained in the 
C program secondary to the higher protein intake consumed by the C group, as 
hypocaloric diets in combination with elevated protein intake have been shown to result 
in increased satiety11, 20-22.  Moreover, exercise induced weight loss has also been 
associated with improved appetite control 31, 32.  Both the C group and W group 
experienced increases in energy, 34.0±55.1 vs. 46.1±85.3 % at 16 weeks.   
 There are several limitations in conducting weight loss clinical trials that should 
be taken into account when interpreting the results of this investigation. First, 
participants who volunteer to participate in weight loss trails are often more motivated to 
adhere to weight loss programs than the general population. Furthermore, study 
participants are continually monitored and encouraged to meet program requirements.  
In our trial, the C group had a compliance rate of 81 % or greater for exercise and the W 
group had 90 % compliance with attendance of weekly meetings. Although these are 
compliance rates for similar to those observed in other long term weight loss trials, 
results may not be generalizable to populations that do not receive similar monitoring 
and support. Second, both of the programs evaluated in this trial have required costs for 
participation in the program. Therefore, utilization of these programs may be limited to 
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populations that can afford to participate in them. Thirdly, the results observed in this 
trial are limited to the population studied, sedentary and obese women, and may not be 
applicable to other populations.  Fourth, this trial lasted for only 4 months. Thus, this 
trial provides no information on maintenance of body composition changes and 
improvements in markers of health and fitness with long term participation in these 
programs. Finally, results are limited to the inherent difficulties in conducting clinical 
trials of this nature, compliance to diet and/or exercise protocols, and accuracy in data 
collection and analysis. 
Conclusion 
In our investigation, participants in both the C group and W groups experienced 
clinically significant weight loss, reductions in BMI, decreased waist and hip 
circumferences, increases in physical activity, improvements in cardiovascular 
endurance and positive changes in biomarkers of cardiovascular disease risk.  However, 
adherence to a higher protein diet in combination with the resistance-based circuit 
training was found to be more efficacious in promoting fat mass loss, preserving fat free 
mass, increasing upper body endurance, and maintaining HDL-c levels. Participants in 
the C group engaged in a greater amount of vigorous recreational activity, while 
participants in the W group had increases in low physical activity. Present results 
support previous findings that participating in a supervised resistance-based exercise 
program may be more efficacious in promoting favorable changes in muscular fitness in 
sedentary obese women compared to a lifestyle based program with encouragement to 
increase physical activity.  Both the C program and W program lead to improved ratings 
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of physical and mental health and eating satisfaction. However, the C group tended to 
experience a greater increase in vitality and emotional stability when dealing with daily 
challenges.  Additionally, feelings of fullness were maintained in the C group, whereas 
the W group experienced a decrease.  Feelings of fullness may have been maintained as 
a result of the higher protein intake consumed by the C group.   
 Our investigation supports the efficacy of both the C program and W program for 
promoting weight loss and improvement in markers of fitness and health.  However, our 
findings suggest adherence to the C program’s higher protein meal-plan based diet and 
supervised resistance-training exercises interspersed with a low-impact calisthenics 
exercise program is more effective in promoting positive body composition changes, 
enhancing muscular fitness, and improving ratings of physical and mental health and 
eating satisfaction than adherence to the W program points based diet plan combined 
with behavior modification advice, group support and encouragement to increase 
physical activity.  
 Commercial weight loss programs have the potential of reaching large numbers 
of overweight or obese individuals.  Conducting randomized and controlled research 
trials on industry sponsored weight control programs will provide conclusions and 
results that health practitioners and governmental agencies can utilize when 
recommending and/or funding programs for overweight and obese populations. Future 
research on commercial weight loss programs should include long-term investigations 
that evaluate the costs of these programs relative to outcome benefits in terms of 
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prevention of obesity related illnesses, improvements in markers of health and 
enhancement of quality of life.   
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APPENDIX A 
 
CONSENT FORM 
 
 
CONSENT FORM 
Comparison of Two Diet Approaches on Weight Loss and Health Outcomes in Women II 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to whether 
or not to participate in this research study.  If you decide to participate in this study, this form will 
also be used to record your consent. 
 
You have been asked to participate in a research project studying the Curves International fitness 
and weight loss program and the Weight Watchers program.  The purpose of this study is to 
determine whether following a Curves high protein/low fat diet for 30-days several times during 16 
weeks of participating in the Curves fitness program promotes stepwise reductions in body weight, 
improvements in body composition, and/or improvements in markers of fitness and health better 
than following the Weight Watchers Momentum Program for the same time period.  You were 
selected to be a possible participant because you met all entrance criteria for this study.  This 
study is being sponsored/funded by Curves International.      
 
What will I be asked to do? 
If you agree to participate in this study, you will first be asked to sign an Informed Consent 
statement in compliance with the Human Subject’s Protection Program (HSPP) at Texas A&M 
University and the American College of Sports Medicine.  You will then be familiarized to the study 
requirements, food log recording and tests to be conducted during the study.  This session will 
take approximately one hour to complete.  Prior to reporting to the lab for baseline testing, you will 
record all food that you eat on dietary record forms for four days (including one weekend day).  
You will not exercise for 48 hours nor eat for 12 hours prior to reporting to the lab for baseline 
testing.  You will then undergo a battery of tests as described in Table 1.  You will fill out a 
Demographic Form, a Health History Form, A Radiation Safety Form, a Quality of Life 
Questionnaire, a Body Image Questionnaire and an eating Satisfaction Questionnaire.  You will 
also be required to report any adverse side effects that you may experience on a weekly basis.  .   
 
You will then continue with the tests as described in Table 1.  You will first be weighed and have 
your resting energy expenditure (REE) determined.  This will involve lying down on an exam table 
and having a light blanket placed over you to keep you warm and placing ear plugs in your ears to 
reduce distractions.  A see through plastic canopy will then be placed over your neck and head so 
that the air that you breathe can be measured for oxygen and carbon dioxide.  You should stay 
motionless without going to sleep for 15-minutes so that your resting energy expenditure can be 
calculated.  You will then donate about 20 milliliters (4 teaspoons) of venous blood from a vein in 
your arm.  Blood samples will be obtained by standard/sterile procedures using a needle inserted 
into a vein in your arm.  Personnel who will be taking your blood are experienced in phlebotomy 
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(procedures to take blood samples) and are qualified to do so under guidelines established by the 
Texas Department of Health and Human Services.  This will take about 5-minutes.  You will then 
have your total body water determined using a bioelectrical impedance analyzer (BIA).  The BIA 
analysis will involve lying down on your back on a table and having two small electrodes placed on 
your right hand and your right foot.  The analyzer wires will be attached and a small and safe 
current (500 micro-amps at a frequency of 5- kHz) will pass through your body so that the amount 
of water can be measured. This analyzer is commercially available and has been used in the 
health care/fitness industry as a means to assess body composition and body water for over 20 
years. The use of this device has been approved by the Food and Drug Administration (FDA) to 
assess total body water and the current to be used has been deemed safe.  Your body 
composition and bone density will then be determined by using a Discovery W dual energy x-ray 
absorptiometer (DEXA). This will involve lying down on your back on the DEXA exam table in a 
pair of shorts or a gown for about 6 minutes.  A low dose of radiation will scan your entire body to 
determine the amount of fat weight, muscle weight, and bone weight. You will be exposed to an x-
ray dose that is similar to the amount of natural background radiation a person would receive in 
one month while living in College Station.  After this test, you will have resting blood pressure 
determined using a blood pressure cuff and stethoscope and heart rate determined by taking your 
pulse.  You will then be prepared to perform a maximal treadmill test.  You will have your right and 
left shoulder, right and left part of your stomach, and several places around your upper chest and 
below your bra line rubbed with alcohol gauze.  Ten (10) electrocardiograph (ECG) electrodes will 
then be placed on your shoulders, chest, and stomach and you will be attached to an ECG to 
evaluate your heart.  You will then be positioned on the treadmill and a sterile mouthpiece will be 
placed in your mouth and a mouthpiece holder will be placed on your head.  A nose clip will be 
placed on your nose and that the air you breathe will be measured for oxygen and carbon dioxide 
content.  Once the equipment is attached, you will be given instructions to begin walking on the 
treadmill.  You will then perform an exercise test that involves increasing the speed and grade you 
are walking on the treadmill until you reach your maximal effort.  Heart rate, ECG tracings, blood 
pressure and your ratings of exertion will be monitored throughout the test.  Once you reach your 
maximum, you will undergo a slow walking and seated recovery period.  This test will take about 
30 minutes to complete.  You will then perform a one repetition maximum (1RM) and 80% of 1RM 
endurance repetition test on the bench press and hip/leg sled using standard procedures.  This 
will involve warming up and performing successive one repetition lifts on the bench press until you 
determine your 1 RM.  You will then rest for 5-minutes and lift 80% of your 1 RM as many times as 
you can.  You will then rest for 10-minutes and follow the same procedure in determining your 1 
RM and 80% of 1 RM on the hip/leg sled.  These tests will take about 20 minutes to complete.  
The same battery of tests will be performed at the post-study assessment 16 weeks into the study 
protocol.  All the assessments minus the exercise tests will also be performed at 4, 6 10 and 12 
weeks into the study protocol.  Each testing session will take between 1.5 and 3 hours to 
complete.  In the event of an emergency during an exercise test proper emergency response 
protocols (calling 9-911 for serious injury or a medical emergency, calling Biosafety/EHS for 
cleanup assistance or spill team response, calling UPD for incidents in public areas, retrieving 
AED located in the lab, performing CPR or other First Aid techniques, etc.)  will be followed by the 
Exercise & Sport Nutrition Laboratory (ESNL) Staff depending on the severity of the emergency.         
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After baseline testing, you will be matched based on age and BMI and randomized into one of 
three intervention groups as described in Table 2.  The first group (n=40) will follow the Curves 
high protein/low fat diet group (30% CHO, 45% PRO, 25% FAT) for 7-days at 1,200 kcals/day and 
then 1,500 kcals/day for 21-days.  If you are assigned to this group you will then consume a 2,200 
kcal/day diet consisting of 45% CHO, 30% PRO, 25% FAT for 14-days during a metabolic 
recovery and weight maintenance phase.  You will diet for 2-days at 1,200 kcals/day only if you 
gain 3 pounds of weight during the maintenance phase.  You will then repeat this entire cycle 
twice and then end with the 30-day weight loss and weight maintenance intervention to determine 
if this is an effective step-wise weight loss plan.  If you are randomized into the second group 
(n=40) you will follow the Weight Watchers Momentum Program that is based on their four pillar 
approach (food, exercise, behavior and support).  Every food has a POINTS value, based on its 
calories, fat and fiber.  The Momentum program uses POINTS values to help keep track of what 
you eat.  A POINTS “budget” will be personalized for you at the weekly meetings.  You will be 
required to attend at least one meeting per week at the local Weight Watchers facility located at 
4001 E. 29th Street, Suite 112 in the Carter Creek Center in Bryan, Texas.  Membership 
dues/passes to the Weight Watchers program/facility will be covered for you during the duration of 
the study.  The third group (n=40) will act as a control group.  If you are assigned to this group you 
will not follow a prescribed nutrition program but will continue with your normal daily habits.  
Everyone, regardless of group assignment, will keep a food record and food frequency log to 
monitor dietary compliance.     
 
If you are randomized to participate in the first group (n=40) you will participate in the Curves 30-
minute fitness program three times per week throughout the investigation.  The Curves program 
involves performing thirteen hydraulic resistance exercise machines that utilize bidirectional 
resistance that work all major muscle groups.  These are interspersed with floor-based 
calisthenics exercises designed to maintain an elevated heart rate.  Research has shown that 
exercise intensity averages 65% of maximal aerobic capacity and that participants generally 
perform 50 – 75% of 1 repetition maximum on the main exercise machines.  The new Curves 
equipment includes the attached force measurement and feedback system.  You will be instructed 
to push hard enough to generate a green light on the feedback panel for each repetition.  All 
exercise sessions will be held in the ESNL.  Research Assistants will monitor your exercise 
sessions and record your attendance.  You will also be encouraged to walk for 30-minutes at a 
brisk pace (60 – 80% of heart rate reserve) on days they do use the Curves equipment.  If you are 
randomized to participate in second group (n=40) you will start by focusing on the food plan and 
then incorporate the specifics of activity a week alter once you have had the chance to get 
conformable with the eating plan.  After a week of reducing sedentary behavior, the POINTS 
Activity System is introduced.  In a way that complements the POINTS values of food, a formula 
that calculates the POINTS values for activity is used.  The formula is based on body weight, the 
amount of time the activity is done, and the level of intensity.  This method enables you to do any 
exercise or activity that is enjoyable and fits within your lifestyle.  If you are assigned to the third 
group (n=40) you will not follow a prescribed exercise program but will continue your normal daily 
habits.  Everyone, regardless of group assignment, will be required to complete activity logs to 
monitor exercise frequency and intensity.       
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Please do your best to:  1) follow the instructions outline by the investigators; 2) show up to all 
scheduled testing and training sessions; and 3) follow the diet prescribed and do not take any 
other nutritional supplements or performance enhancing aids during this study (i.e., 
vitamins/minerals, creatine, HMB, androstenedione, DHEA, etc).  In addition, please do not take 
any non-medically prescribed medications and report any medication that is prescribed for you to 
take during this study.  If you take any other nutritional supplements or medications during the 
course of the study that may affect vitamin/mineral status, body composition, or strength you may 
be removed from the study.     
 
What are the risks involved in this study? 
The risks associated with this study are:  You will be exposed to a low level of radiation during the 
DEXA body composition tests, which is similar to the amount of natural background radiation you 
would receive in one month while living in College Station.  In addition, a very low level of 
electrical current will be passed through your body using a bioelectrical impedance analyzer (BIA). 
This analyzer is commercially available and has been used in the health care/fitness industry as a 
means to assess body composition and body water for over 20 years.  The use of the BIA and 
DEXA analyzers have been shown to be safe methods of assessing body composition and total 
body water and are approved by the FDA.  You will donate about 4 teaspoons (20 milliliters) of 
venous blood six (6) times during the study using standard phlebotomy procedures.   This 
procedure may cause a small amount of pain when the needle is inserted into the vein as well as 
some bleeding and bruising. You may also experience some dizziness, nausea, and/or faint if you 
are unaccustomed to having blood drawn.  The exercise tests that will be performed may cause 
symptoms of fatigue, shortness of breath, and/or muscular fatigue/discomfort.  The exercise tests 
may also cause short-term muscle soreness and moderate fatigue for several days following the 
tests.  You may also experience muscle strains/pulls during the exercise testing and/or training 
program.  However, exercise sessions will be conducted by trained personnel and monitored to 
ensure you follow appropriate exercise guidelines.  You will follow a prescribed dietary regimen 
involving consuming 1,200, 1,500 or 2,200 calories per day during various phases of the program.  
In addition, one group will ingest a high percentage of calories in the form of protein.  Although the 
total amount of total protein is not excessive (100-220 grams/day or 1.1 - 2.3 grams/kg/day for a 
95 kg female) it may be higher than you are accustomed to ingesting and may exceed 
recommended protein intake for active individuals (i.e., 1-2 grams/kg/day).  As a result, you may 
experience weight loss or gain, feelings of hunger or fullness, and/or changes in appetite and/or 
mood during various phases of the dietary intervention.      
What are the possible benefits of this study? 
The possible benefit you may receive from participation in this study is increased physical fitness and 
improvements in body composition.  You may also gain insight about your health and fitness status from 
the assessments that will be performed.        
Do I have to participate? 
No.  Your participation is voluntary.  You may decide not to participate or to withdraw at any time 
without your current or future relations with Texas A&M University being affected.   
 
Will I be compensated? 
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You will receive $175 (i.e., $25 for each familiarization and experimental session) upon completion 
of the study.  Disbursement will occur upon completion of all sessions and after all study related 
materials (food logs, training logs, etc.) are turned in.  Participants who discontinue, or are 
dropped prior to completion will be compensated on a pro-rated basis depending on the total 
number of sessions completed (i.e., $25 for each familiarization and experimental session).  
Participants will be dropped if they are non-compliant with any portion of the study requirements at 
the discretion of the Principal Investigator, Dr. Richard Kreider.       
 
Who will know about my participation in this research study? 
The records of this study will be kept private.  No identifiers linking you to this study will be 
included in any sort of report that might be published.  Research records will be stored securely 
and only Mr. Christopher Rasmussen and Dr. Richard Kreider will have access to the records.   
 
Whom do I contact with questions about the research?  
If you have questions regarding this study, you may contact Dr. Richard Kreider, 945-1333, 
rkreider@hlkn.tamu.edu or Mr. Christopher Rasmussen, crasmussen@hlkn.tamu.edu.  
 
Whom do I contact about my rights as a research participant?   
This research study has been reviewed by the Human Subjects’ Protection Program and/or the 
Institutional Review Board at Texas A&M University.  For research-related problems or questions 
regarding your rights as a research participant, you can contact these offices at (979)458-4067 or 
irb@tamu.edu. 
 
 
 
Signature   
Please be sure you have read the above information, asked questions and received answers to 
your satisfaction.  You will be given a copy of the consent form for your records.  By signing this 
document, you consent to participate in this study. 
 
Signature of Participant: ___________________________________   Date: ______________ 
 
Printed Name:_________________________________________________________________   
 
Signature of Person Obtaining Consent: _____________________    Date: ______________ 
 
Printed Name: _________________________________________________________________ 
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APPENDIX B 
 
INFORMATION SHEET 
 
 
 
INFORMATION SHEET 
Comparison of Two diet Approaches on Weight Loss and Health Outcomes in Women II 
 
Introduction 
The purpose of this form is to provide you (as a prospective research study participant) 
information that may affect your decision as to whether or not to participate in this research. 
 
You have been asked to participate in a research study involving the Curves International fitness 
and weight loss program and the popular Weight Watchers program.  The purpose of this study is 
to compare the Curves fitness and weight loss program to the Weight Watchers Momentum 
Program.      
 
What will I be asked to do? 
If you agree to participate in this study, you will be asked to complete each of the following:   
- Read and sign an Informed Consent statement   
- Attend a Familiarization session detailing the requirements of the study  
- Complete a series of 6 forms/questionnaires   
- Complete a body weight assessment    
- Complete a resting energy expenditure (REE) assessment   
- Donate approximately 20 milliliters (4 teaspoons) of venous blood   
- Complete a total body water assessment using a bioelectrical impedance analyzer 
(BIA) 
- Complete a body composition/ bone density assessment using a dual energy x-ray 
absorbtiometer (DEXA)  
- Complete a resting blood pressure (BP) assessment 
- Complete a resting heart rate (HR) assessment  
- Complete a graded exercise test (GXT)  
- Complete a 1 repetition maximum (1RM) & 80% of 1RM test on the bench press and 
leg press 
- Complete an exercise and diet intervention program lasting a total of 16 weeks 
- Call a Research Assistant on a weekly basis to report progress in the study 
- Complete some or all of these same testing procedures following 4, 6, 10, 12 and 16 
weeks of training and dietary intervention as described in Table 1   
 
What are the risks involved in this study? 
The possible risks associated with this study are:  
- Exposure to a low level of radiation during the DEXA body composition assessment 
- Exposure to a very low level of electrical current during the BIA assessment 
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- Possible pain, bleeding, bruising, and/or dizziness or nausea during the phlebotomy 
procedure 
- Possible fatigue, shortness of breath, and/or muscular fatigue during the exercise 
tests  
- Possible weight loss/gain, feelings of hunger/fullness and/or changes in appetite 
and/or mood during different phases of the dietary intervention     
 
What are the possible benefits of this study? 
The possible benefits associated with this study are:  
- Increased physical fitness and improvements in body composition  
- Insight into personal health and fitness status from the assessments performed 
 
  
Do I have to participate? 
No.  Your participation is voluntary.  You may decide not to participate or to withdraw at any time 
without your current or future relations with Texas A&M University being affected.   
 
Will I be compensated? 
You will receive $275 (i.e., $25 for each familiarization and experimental session).  Disbursement 
will occur upon completion of all sessions and after all study related material (food logs, training 
logs, etc.) are turned in.   
 
Who will know about my participation in this research study? 
The records of this study will be kept private.  No identifiers linking you to this study will be 
included in any sort of report that might be published.  Research records will be stored securely 
and only Mr. Christopher Rasmussen and Dr. Richard Kreider will have access to these records.  
 
Whom do I contact with questions about the research?  
If you have questions regarding this study, you may contact Dr. Richard Kreider, 945-1333, 
rkreider@hlkn.tamu.edu or Mr. Christopher Rasmussen, crasmussen@hlkn.tamu.edu.  
 
Whom do I contact about my rights as a research participant?   
This research study has been reviewed by the Human Subjects’ Protection Program and/or the 
Institutional Review Board at Texas A&M University.  For research-related problems or questions 
regarding your rights as a research participant, you can contact these offices at (979)458-4067 or 
irb@tamu.edu. 
 
Participation 
Please be sure you have read the above information, asked questions and received answers to 
your satisfaction.  If you would like to be in the study you will now be scheduled for a 
familiarization session.  
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APPENDIX C 
 
MEDICAL HISTORY QUESTIONNAIRE 
 
 
Texas A&M UNIVERSITY 
                                                     EXERCISE & SPORT NUTRITION LABORATORY 
 
Medical History Inventory 
 
Directions.  The purpose of this questionnaire is to enable the staff of the Exercise and 
Sport Sciences Laboratory to evaluate your health and fitness status.  Please answer the 
following questions to the best of your knowledge.  All information given is 
CONFIDENTIAL as described in the Informed Consent Statement. 
  
Name:____________________________________________ Age _____ 
Date of Birth_______________ 
 
Name and Address of Your Physician:_______________________________________ 
______________________________________________________________________ 
 
MEDICAL HISTORY 
 
Do you have or have you ever had any of the following conditions? (Please write the 
date when you had the condition in the blank). 
 
____Heart murmur, clicks, other cardiac findings?     ____ Asthma/breathing difficulty?  
____Frequent extra, skipped, or rapid heartbeats?   ____Bronchitis/Chest Cold? 
____Chest Pain of Angina (with or without exertion)?____Cancer, Melanoma, or  
                                                                                              Suspected Skin Lesions 
____High cholesterol?     ____ Emphysema/lung disease 
____Heart attack or any cardiac surgery?   ____ Epilepsy/seizures? 
____Leg cramps (during exercise)?    ____ Rheumatic fever? 
 ____Chronic swollen ankles?     ____ Scarlet fever? 
____Varicose veins?      ____ Ulcers? 
____Frequent dizziness/fainting?    ____ Pneumonia? 
____Muscle or joint problems?    ____ Anemias? 
____High blood sugar/diabetes?    ____ Liver or kidney disease 
____Thyroid Disease?     ____ Autoimmune disease? 
____Low testosterone/hypogonadism?   ____ Nerve disease? 
____Glaucoma?      ____ Psychological Disorders? 
 
 
Do you have or have you been diagnosed with any other medical condition not listed?  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
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Please provide any additional comments/explanations of your current or past medical 
history.  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
Please list any recent surgery (i.e., type, dates etc.).  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________ 
 
List all prescribed/non-prescription medications and nutritional supplements you have 
taken in the last 3 months.  
_______________________________________________________________________
_______________________________________________________________________ 
 
What was the date of your last complete medical exam? 
_______________________________________________________________________
_______________________________________________________________________ 
 
Do you know of any medical problem that might make it dangerous or unwise for you to 
participate in this study? (including strength and maximal exercise tests)  ____ If yes, 
please expain.____________________________________________________________ 
_______________________________________________________________________ 
 
Recommendation for Participation (for ESNL use only):   
 
____ No exclusion criteria presented. Subject is cleared to participate in the study. 
____ Exclusion criteria is/are present. Subject is not cleared to participate in the study. 
 
Signed: ___________________________________ Date: ________________________ 
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APPENDIX D 
 
PERSONAL INFORMATION WORKSHEET 
 
 
Texas A&M University 
EXERCISE & SPORT NUTRITION LABORATORY 
 
 
Personal Information 
 
Name:  
____________________________________________________________________________
                                                                                                                                                  
Address:  
____________________________________________________________________________ 
                                                                                                                                                  
 
City:                                        State:                Zip Code               
 
Home Phone:     (      ) ____________________  Work Phone: (      ) ____________________                                
 
Beeper:  (      ) ____________________  Cell Phone: (      ) ____________________
  
Fax:  (      )                               E-mail address: _________________________ 
 
Birth date:            /            /              Age:  ________ Height:  _________Weight:  __________                 
 
 
Exercise History/Activity Questionnaire 
 
1. Describe your typical occupational activities. 
 
 
2. Describe your typical recreational activities 
 
 
3. Describe any exercise training that you routinely participate.  
 
 
4. How many days per week do you exercise/participate in these activities? 
 
 
5. How many hours per week do you train? 
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6. How long (years/months) have you been consistently training? 
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APPENDIX E 
 
DATA COLLECTION FORM 
 
 
 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial: Comparison of Two Diet Approaches on Weight Loss and Health Outcomes in 
Women II    
     
Demographics                   ESNL Staff Initials:  _____ 
Name: _____________________Testing Session:  _____ Group:  _____   
Date:  _____      D.O.B.:  _____  Age:  _____ 
 
Resting Measures                    ESNL Staff Initials:  _____ 
 
Psychological Questionnaires/Informed Consent:  
 
HLKN Informed consent:  _____                  Body Image:  _____ 
Radiation consent:  _____                   MOS SF-36:  ____ 
Activity Log:  _____         Eating Satisfaction:  _____ 
Food Log:  _____   Post-Study Questionnaire (T6 only):  _____
     
Physiological Parameters:     ESNL Staff Initials:  _____ 
 
Height:   _____ in.      Waist: _____in.  
Weight:   _____ lb.      Hip:  _____in.  
REE #1:  _____     Resting H.R.: _____bpm.  
Time:   _____am    Resting B.P.:_____/_____mmHg 
Last Meal:   _____am/pm    BIA: _____ 
Hrs Fasted: _____hr.     Handheld BIA:  _____ #1 or #2 
Last Wkout: _____     DEXA #2:   _____ 
Lab (EBNL): _____ (2) SST Tubes/ (1) EDTA  ECG (Rest): _____ #1 or #2 
Time:   _____am    Max Test:     _____ #1 or #2 
Yr. /Menopause _______   Notes:   _____  
 
Exercise Measures:  Strength Testing:   ESNL Staff Initials:  ____ 
 
Leg Press:  Foot Position:  _____ Sled Position:  _____  
Preceding Weights/Reps:   
_____x_____: _____x_____: _____x_____: _____x_____: _____x_____ 
1 RM:  _____     80% 1RM:  _____ 80% 1RM repetitions:  _____ 
 
Bench Press:  Hand Position:  _____  
Preceding Weights/Reps:   
_____x_____: _____x_____: _____x_____: _____x_____: _____x_____ 
1 RM:  _____ 80% 1RM:  _____ 80% 1RM repetitions:  _____ 
